

## POSTER PRESENTATIONS

SESSION	POSTER #	ABSTRACT TITLE	PRESENTING AUTHOR
FRIDAY	ACTR-01	Safety Analyses of Tumor Treating Fields in Combination with Lomustine in the EF14 Phase 3 Clinical Study	Adrian Kinzel
FRIDAY	ACTR-03	A Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma	Lisa Rogers
SATURDAY	ACTR-06	Initial Results of a Phase I Study of Procaspase Activating compound-1 (PAC-1) in Combination with Temozolomide for Recurrent Malignant Glioma	Martin Nicholas
FRIDAY	ACTR-07	Complete, Durable Response of a Recurrent Unresectable Grade III Glioma to a Repurposed Drug Regimen	Richard Kast
SATURDAY	ACTR-10	A Randomized, Phase I/II Trial of Ixazomib in Combination with Standard Therapy for Upfront Treatment of Patients with Newly Diagnosed MGMT Methylated Glioblastoma (GBM) –study Design	Xiao-Tang Kong
FRIDAY	ACTR-19	A Multicenter Pilot Phase II Study of Continuing TMZ with the Addition of Disulfiram and Copper for Refractory Glioblastoma	Jiayi Huang
SATURDAY	ACTR-20	A Small Molecule AXL Inhibitor, BGB324 – First-in-human GBM Surgical PK Trial for Recurrent Tumors	Sadashib Ghosh
FRIDAY	ACTR-21	Management of Ocular Side Effects in Patients with Egfr-amplified Glioblastoma Receiving Depatuxizumab Mafodotin	Maria Guseva
FRIDAY	ACTR-23	Safety of Intra-arterial Chemotherapy with Osmotic Opening of the Blood-brain Barrier	Prakash Ambady
FRIDAY	ACTR-25	Updated Results from a Prospective, Randomized Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with Avastin versus Avastin Alone	Brandon Konkel
SATURDAY	ACTR-26	A Feasibility Study of the Nativis Voyager® System in Patients with Newly Diagnosed Glioblastoma (GBM)	Garni Barkhoudarian
FRIDAY	ACTR-27	Phase 2 Study of Dianhydrogalactitol (VAL-083) in Patients with Mgmt-unmethylated, Bevacizumab-naïve Recurrent Glioblastoma	Anne Steino
SATURDAY	ACTR-28	Phase 1 Dose Escalation Trial of the Safety of BMX-001 Concurrent with Radiation Therapy and Temozolomide in Newly Diagnosed Patients with High-grade Gliomas	Katherine Peters
SATURDAY	ACTR-32	5-ALA Fluorescence Is a Powerful Marker for Detection of Unexpected Glioblastoma Tissue During Surgery of Radiologically Suspected Low-grade Gliomas	Petra A. Mercea
FRIDAY	ACTR-35	Molecular Matchmaking: Efficacy of Early Clinical Trials Guided by Next-generation Sequencing in Patients with Glioblastoma Multiforme	Jacob Leary
SATURDAY	ACTR-42	The Use of Advanced Diffusion MRI Parameters in the Assessment of Treatment Response in Glioblastoma Using Multi-b Value Acquisition and a Histogram-based Approach	Shah Islam
SATURDAY	ACTR-44	Preliminary Results from the NCT02770378 Proof-of-concept Clinical Trial Assessing the Safety of the cusp9v3 Protocol Combined with Metronomic Temozolomide for Recurrent Glioblastoma	Marc-Eric Halatsch
SATURDAY	ACTR-48	Feasibility of Discontinuation of Adjuvant Temozolomide After 12 Cycles Remaining Without Progression for Patients with Newly Diagnosed Glioblastoma	Motoo Nagane

FRIDAY	ACTR-49	Pricotff: A Phase I/II Trial of Tumor Treating Fields Prior and Concomitant to Radiotherapy in Newly Diagnosed Glioblastoma	Martin Glas
SATURDAY	ACTR-50	Effect of Concurrent and Adjuvant Temozolomide on Survival in Patients with Newly Diagnosed Grade III Gliomas Without 1p/19q Co-deletion: A Randomized, Open-label, Phase 2 Study (Interim Results from the KNOG-1101 Study)	Chae-Yong Kim
FRIDAY	ACTR-51	Phase 2 Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of pi3k/mtor Inhibitor GDC-0084 Given to Glioblastoma (GBM) Patients with Unmethylated o6-methylguanine-methyltransferase Promoter Status	Patrick Wen
SATURDAY	ACTR-52	Tumor Treating Fields (TTFIELDS) in Combination with Lomustine (CCNU) in the EF-14 Phase 3 Clinical Study – A Safety Analysis	Adrian Kinzel
FRIDAY	ACTR-53	STEAM / EORTC 1608: Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients with Anaplastic Astrocytoma or Glioblastoma - A Phase 1b Study	Emilie Le Rhun
SATURDAY	ACTR-54	Pattern of Recurrence and Impact on Survival of Salvage Therapies in Low-grade Gliomas Following Dose-dense Temozolomide	Alessia Pellerino
FRIDAY	ACTR-57	Relative Cerebral Blood Volume (rCBV) as Response Predictor in the Treatment of Recurrent Glioblastoma (GB) with Antiangiogenic Therapy	Enrique Gomez-Figueroa
SATURDAY	ACTR-58	Treatment Outcomes of Stereotactic Radiotherapy Combined with Bevacizumab Therapy in recurrent Glioblastoma Patients	Yukihiko Sonoda
FRIDAY	ACTR-59	Improving the Intra-operative Diagnosis of High-grade Glioma Using a Fluorescence Biomarker – Result of the GALA-BIDD Study	Colin Watts
SATURDAY	ACTR-62	Phase I/II Study Of Temozolomide Plus Nimustine Chemotherapy For Recurrent Malignant gliomas: kyoto Neuro-oncology Group	Tomokazu Aoki
FRIDAY	ACTR-63	Treatment and Survival of Patients with Lower Grade Glioma According to the 2007 and the 2016 WHO Classification: A Retrospective Analysis of 423 Patients	Oliver Baehr
FRIDAY	ACTR-65	Intrathecal Pemetrexed for Patients with Recurrent Leptomeningeal Metastasis from Lung Adenocarcinoma: a Phase I Clinical Trial (IPRLM,NCT03101579)	Zhenyu Pan
SATURDAY	ACTR-66	Bevacizumab Therapy for the Treatment of Adult Glioblastoma: Systematic Review & Meta-analysis	Nagham Kaka
SATURDAY	ACTR-68	Initial Treatment of GBM with a Ketogenic Diet Along with Radiation and Chemotherapy: Feasibility, Toxicity and Response	Kenneth Schwartz
FRIDAY	ACTR-69	Blood Derived Exosomal Htert Mrna - A Potential Biomarker for Glioblastoma	Tali Siegal
SATURDAY	ACTR-70	Increasing Survival in Biopsy-only GBM Patients	John Gainer
FRIDAY	ACTR-71	Phase 1/2 Study of Dianhydrogalactitol (VAL-083) with Radiation Therapy in Patients with Newly Diagnosed, Mgmt-unmethylated Glioblastoma	Anne Steino
SATURDAY	ACTR-72	Idh-wild Type Grade II Gliomas: A Retrospective Series of Italian Association of Neuro-oncology	Roberta Rudà
FRIDAY	ANGI-01	Correlation Between Histological and MRI Measures of Infiltration in a Preclinical Glioblastoma Model	Gerard Thompson
SATURDAY	ANGI-02	A Critical Role for LARG in Rhoc Mediated Glioblastoma Cell Invasion	Zonghui Ding
FRIDAY	ANGI-03	PSA-NCAM in Glioblastoma – A Negative Prognostic Marker and a Therapeutic Target?	Thomas Park
SATURDAY	ANGI-04	TEAD1 Regulates Cell Migration in Human Glioblastoma in Part Through Emt-associated Cadherins	Jessica Tome-Garcia

FRIDAY	ANGI-09	Circulating mir-10b and mir-21 in Patients with Gbm Treated with Bevacizumab Are Secreted to the Circulation by Proteins and Their High Quantification Is Probably the Result of Drug-induced Tumor Hypoxia	Iris Lavon
SATURDAY	ANGI-10	WSD1227: A Brain Penetrable VEGFR2 Inhibitor for the Treatment of Primary and Metastatic Brain Tumors	Jinqiang Zhang
FRIDAY	ANGI-11	Tumor Treating Fields (TTFields) Inhibit Cancer Cell Migration and Invasion by Inducing Reorganization of the Actin Cytoskeleton and Formation of Cell Adhesions	Moshe Giladi
SATURDAY	ANGI-12	Mri-based Cell Tracking with Individual Cell Sensitivity for Measuring Cancer Cell Invasion	Dorela Shuboni-Mulligan
FRIDAY	ANGI-13	Tenascin-c Induces Vasculogenic Mimicry Formation in Glioblastoma Through AKT Pathway	Hai-ping Cai
SATURDAY	ANGI-16	Early Detection of Tumor Cell Proliferation Is Associated with a Unique Radiomic Biomarker in Preclinical Glioblastoma Xenograft and Patients	Islam Hassan
FRIDAY	ANGI-17	Interleukin 1 Signaling Regulates Blood-brain Barrier Integrity in Glioblastoma	Cameron Herting
SATURDAY	ANGI-18	Autocrine Cycle of Bone Morphogenetic Protein 4 (BMP4) Enhances Tumor Aggressiveness in <i>idh1</i> -mutated Gliomas	Yiqiang Zhou
SATURDAY	ATIM-02	Tumor Treating Fields in Combination with Bevacizumab in Recurrent or Progressive Meningioma in a Phase 2 Study	Priya Kumthekar
FRIDAY	ATIM-03	TTFields and Pulsed Bevacizumab in Patients with Bevacizumab-refractory Recurrent Glioblastoma: A Phase 2 Study	David Tran
FRIDAY	ATIM-05	Intratumoral Delivery of MDNA55, an interleukin-4 Receptor Targeted Immunotherapy, by Mri-guided Convective Delivery for the Treatment of Recurrent Glioblastoma	Achal Achrol
SATURDAY	ATIM-08	A Phase I Trial of Pembrolizumab and Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma (NCT03426891)	Solmaz Sahebjam
FRIDAY	ATIM-13	Asunercept Plus Radiotherapy in Relapsed Glioblastoma. Update on Five Years Overall Survival of Study NCT01071837 and Development of a Population-pk - Tumor Growth Inhibition - Survival Model	Harald Ficke
FRIDAY	ATIM-14	CMV gb/pp65 Evlps Formulated with GM-CSF as a Therapeutic Vaccine Against Recurrent Glioblastoma (GBM)	Andrew B. Lassman
FRIDAY	ATIM-15	A Phase 1 Study of ad-rtshil-12 + Velelimex in Adults with Recurrent Glioblastoma: Dose Determination with Updated Overall Survival	E. Antonio Chiocca
SATURDAY	ATIM-18	A Phase I Trial of Vaccination with Autologous Dendritic Cells Pulsed with Lysate Derived from an Allogeneic Glioblastoma Stem-like Cell Line for Patients with Newly Diagnosed or Recurrent Glioblastoma	Jethro Hu
SATURDAY	ATIM-20	GAPVAC-101 Trial of a Highly Personalized Peptide Vaccination for Patients with Newly Diagnosed Glioblastoma	Wolfgang Wick
FRIDAY	ATIM-21	Updated Results of a Phase I Trial of anti-lag-3 or anti-cd137 Alone and in Combination with anti-pd-1 in Patients with Recurrent GBM	Michael Lim
SATURDAY	ATIM-22	Prognostic Value of PTEN Loss in Newly Diagnosed GBM Patients Treated with Autologous Heat Shock Protein Vaccine	Paula Alcaide Leon
SATURDAY	ATIM-24	Interim Results of a Phase II Multicenter Study of the Conditionally Replicative Oncolytic Adenovirus DNX-2401 with Pembrolizumab (Keytruda) for Recurrent Glioblastoma; CAPTIVE Study (KEYNOTE-192)	Gelareh Zadeh

SATURDAY	ATIM-26	Immunologic Trends Associated with Patient Outcomes in a Phase 1 Clinical Trial of Toca 511 and Toca FC in Recurrent High Grade Glioma	William Accomando
FRIDAY	ATIM-29	NRG BN002: safety Data from a Phase I Study of Ipilimumab (IPI), Nivolumab (NIVO), and the Combination for Newly Diagnosed Glioblastoma (GBM)	Mark Gilbert
SATURDAY	ATIM-30	How to Monitor Immunogenic Cell Death in Patients with Glioblastoma	Stefaan Van Gool
FRIDAY	ATIM-31	Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients with Newly Diagnosed Glioblastoma	Adilia Hormigo
SATURDAY	ATIM-34	Targeting the CD200 Checkpoint for the Fight Against Central Nervous System Tumors	Michael Olin
FRIDAY	ATIM-35	VXM01 Phase I Study in Patients with Progressive Glioblastoma – Final Results	Wolfgang Wick
SATURDAY	ATIM-36	Dose Escalation Trial of D2C7 Immunotoxin (D2C7-IT) Administered Intratumorally via Convection-enhanced Delivery (CED) for Recurrent Malignant Glioma (MG)	Annick Desjardins
SATURDAY	ATIM-38	Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 (durvalumab, Durva) + Bevacizumab (BEV) in Bev-naïve Patients with Recurrent Glioblastoma (GBM)	David Reardon
SATURDAY	ATIM-42	Safety and Efficacy of Autologous Dendritic Cells/tumor Cell Antigen Adjuvant Therapy of Glioblastoma Multiforme: Results of 59 Cases	Wen-Kuang Yang
FRIDAY	CBMT-01	paraoxonase-2 Is Highly Expressed in GBM and Promotes GBM Cell Survival	Hae-Ri Song
SATURDAY	CBMT-02	mir-124, -128, and -137 Combination Therapy Against Glioblastoma	Adam Kostli
FRIDAY	CBMT-03	A Novel Metabolic PET Tracer Strategy to Determine Early Effects of Tumor Treating Fields (TTFields)	Chirag Patel
FRIDAY	CBMT-05	Role of the let7-eef2k Axis in Myc-driven Medulloblastoma Adaptation to Nutrient Deprivation	Alberto Delaidelli
FRIDAY	CBMT-07	Evaluation of Glycolytic Response to Seven Classes of Anti-glioblastoma Drugs by Non-invasive Measurement of Pyruvate Kinase M2	Corinne Beinat
SATURDAY	CBMT-08	Comparison of Three Metabolic PET Radiotracers in Glioblastoma: Cell Culture and Animal Studies	Corinne Beinat
FRIDAY	CBMT-09	Establishment and <i>in vitro</i> Characterization of a Sporadic Pediatric Atypical Meningioma Cell Line	Desmond Brown
FRIDAY	CBMT-11	Peroxisomal Fatty Acid Oxidation in Glioblastoma During Hypoxia	Laura Caflisch
SATURDAY	CBMT-12	Fatty Acid Synthase Positive Evs as Novel Biomarkers in Brain Cancer	Franz Ricklefs
FRIDAY	CBMT-13	Unravelling Metabolism of Glioblastoma Using Mass Spectrometry Imaging	Jyotsna Upendra Rao
SATURDAY	CBMT-14	Exploiting Vulnerabilities of the Mesenchymal Subtype of Glioma Stem-like Cells to Endoplasmic Reticulum Stress	Alessandra Audia
SATURDAY	CBMT-16	A Combination Strategy to Counteract Pten-deficiency by Targeting the S6 and TAM Kinases in Glioblastoma	David Plas
FRIDAY	CBMT-17	Novel Approach of Utilising Serum/plasma EV and Cell-free RNA for Treatment Monitoring in Glioblastoma Patients	Theophilos Tzaridis
FRIDAY	CBMT-19	RNU6-1 Analysed in Exosomes from Sera as a Novel Differential Biomarker for GBM vs Non-neoplastic Brain Lesions and NSCPL	Maidier Varela-Guruceaga
SATURDAY	CBMT-20	A Ketogenic Pill for Glioblastoma	Hassan Azari
FRIDAY	CBMT-21	Alterations of Cysteine Metabolism in Genetic Variants of High Grade Gliomas	Mirna Lechpammer

SATURDAY	CBMT-24	Mitochondrial DNA Content in Glioblastoma and Its Clinical Significance	Palavalasa Sravya
FRIDAY	CBMT-25	Anti-tumor Effect of VEGF Inhibitor Plus Ketogenic Diet Therapy for Glioblastoma	Masahiro Maeyama
SATURDAY	CBMT-26	High Mobility Group At-hook 2 (HMGA2) Is a Prognostic Factor Associated with Malignant Phenotype in Medulloblastomas	Yoshiki Arakawa
FRIDAY	CBMT-27	Proteomic Map of Glioma Biopsies Reveals Functional Defects in Endocytosis	Jean-Louis Boulay
SATURDAY	CBMT-28	The Prosurvival Role of Heme oxygenase-1 and Its Regulation by Egrviii in Glioblastoma: Surgical and Photodynamic Therapy Applications	Andrea Fontana
FRIDAY	CBMT-29	Induction of Autophagy Following TFields Application Serves as a Survival Mechanism Mediated by AMPK Activation	Moshe Giladi
FRIDAY	CBMT-31	Quiescent Glioblastoma Cells Shift to an Epithelial-mesenchymal Transition (EMT) -like Gene Program	Rut Tejero
FRIDAY	CBMT-33	Alternating Electric Fields Induced by Fast Spinning Strong Magnets Modulate Mitochondrial Energy Metabolism in GBM Cells	Kumar Pichumani
SATURDAY	CBMT-34	Targeting the Rna-processing Gene <i>magoh</i> as a Novel Therapy for Medulloblastoma	Jennifer Ocasio
SATURDAY	CBMT-36	GRK2 Promotes Medulloblastoma Growth and Survival	Anup Pathania
SATURDAY	CBMT-38	Association of <i>mir-146a</i> >g, <i>mir-149c</i> >t, <i>mir-196a2c</i> >t, and <i>mir-499a</i> >g Polymorphisms with Brain Tumors	Jaejoon Lim
SATURDAY	CBMT-42	Loss of Promoter Methylation in Glycolytic Genes Is Associated with Aggressiveness in idh1-mutant Lower Grade Gliomas	Mioara Larion
FRIDAY	CBMT-43	Single Live Tumor Cell Metabolism via Raman Imaging Microscopy	Adrian Lita
SATURDAY	CBMT-44	Metabolic Plasticity and Heterogeneity in idh1 <i>mut</i> Cell Lines Produces Resistance to Glutaminase Inhibition by CB839	Victor Ruiz Rodado
FRIDAY	CBMT-45	A Novel C-circle Assay for Detecting Alternative Lengthening of Telomeres (ALT) Mechanisms	Humaira Noor
SATURDAY	CBMT-46	Microenvironment-derived Mitochondria Prime Glioma Chemoresistance by Augmenting NAD+ Metabolism and Parp-dependent DNA Repair	Yang Liu
FRIDAY	CBMT-47	The Role of phosphofructokinase-1 in Glioblastoma Maintenance and Motility	Kamilla Jensen
FRIDAY	CMET-01	Clinical and Dosimetric Factors Related to Radiation Necrosis After Five Fraction Radiosurgery for Resected Brain Metastases	Zachary Buchwald
FRIDAY	CMET-03	Phase 1 Trial of Osimertinib with Stereotactic Radiosurgery in EGFR Mutant Lung Cancer Brain Metastasis	Bicky Thapa
SATURDAY	CMET-04	Metastatic Gastrointestinal Cancer to the Skull Base Mimicking NF2	Phioanh Nghiemphu
FRIDAY	CMET-05	Association Between Tumor Location and Toxicity Outcomes After Stereotactic Radiosurgery for Brain Metastases	Colette Shen
SATURDAY	CMET-06	Distant Brain Failure and Salvage Free Survival for Radiosurgery-treated Melanoma Brain Metastases in the Era of Checkpoint Inhibitor Immunotherapy	Steven Nguyen
FRIDAY	CMET-07	Frailty Predicts Mortality After Resection of Brain Metastases	Saksham Gupta
SATURDAY	CMET-08	Brain Metastases as Primary Presentation of Solid Tumors: A Descriptive Analysis of the National Cancer Database (NCDB)	Catherine Garcia

FRIDAY	CMET-09	Impact of Steroids on the Efficacy of Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Brain Metastases	Bicky Thapa
SATURDAY	CMET-10	Risk of Radiation Necrosis Following Repeat Stereotactic Radiosurgery for Recurrent Brain Metastases	Daria Krivosheya
FRIDAY	CMET-11	Leptomeningeal Melanoma Metastasis Presenting as Intraventricular and Subarachnoid Hemorrhage	Maya Graham
SATURDAY	CMET-12	Distant Brain Failure Following Stereotactic Radiosurgery for Brain Metastases from Breast Cancer	Andrew Keller
SATURDAY	CMET-14	Distant Brain Failure Following Stereotactic Radiosurgery for Brain Metastases from Non-small Cell Lung Cancer	Andrew Keller
FRIDAY	CMET-15	Whole Exome Sequencing of Brain Metastases from Colorectal Primary Cancers Reveals Clinically Actionable Mutations	Matthew Strickland
SATURDAY	CMET-16	The Role of Surgical Resection of Melanoma Brain Metastases in the Immunotherapy Era	Christopher Alvarez-Breckenridge
FRIDAY	CMET-17	Ventriculomegaly After Stereotactic Radiosurgery for Brain Metastases	Ali Alattar
FRIDAY	CMET-23	Natural History and Risk Factors for Cystic Formation After Stereotactic Radiosurgery for Brain Metastasis	Ali Alattar
SATURDAY	CMET-24	Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis	Kate Grimsrud
FRIDAY	CMET-25	Neoplastic Meningitis Registry: Use of Multi-national Collaborative Efforts to Uncover Trends and Improve Outcomes in Leptomeningeal Disease	Shwetha Srikanth
SATURDAY	CMET-26	Perioperative Imaging of Brain Metastases: A European Association of Neuro-oncology (EANO) Youngsters Survey	Barbara Kiesel
FRIDAY	CMET-29	Pre-operative Dural Contact Is Associated with Surgical Cavity Recurrence After Post-operative Stereotactic Radiosurgery	Matthew Susko
FRIDAY	CMET-31	Intracerebral Hemorrhage from Neoplastic Aneurysm as First Manifestation of Lung Cancer	Maria Diaz
SATURDAY	CMET-32	Bilateral Occipital Metastases: Management Considerations and Cortical Blindness	Mark Zaki
FRIDAY	CMET-35	Diffusion and Perfusion Features of Metastatic Brain Lesions	Ararat Chakhoyan
SATURDAY	CMET-36	Bevacizumab with or Without Lomustine for Metastatic Orbital, Dural and Leptomeningeal Esthesioneuroblastoma	Richard Green
FRIDAY	CMET-37	Sustained Clinical and Radiographic Response in an Adult Patient with Leptomeningeal Metastases from Acute Myeloid Leukemia Treated with Intraventricular Methotrexate	Roy Allan Dominique Torcuator
SATURDAY	CMET-38	Impact on the Clinical Course of EGFR Mutation on Brain Metastases from Non-small-cell Lung Cancer from Viewpoint of Neuro-oncologists	YUYA FUJITA
SATURDAY	CMET-40	Long-lasting Response in Spinal Metastases from ALK Rearranged Non-small-cell Lung Cancer Treated with Different ALK Inhibitors	Alessia Pellerino
FRIDAY	CMET-41	Lifetime Lung, Breast, and Skin Cancer brain Metastases Incidence: A Reproducible Seer-medicare Study	Mustafa Ascha
SATURDAY	CMET-42	Bone Metastasis Predicts Poor Prognosis of Patients with Brain Metastases from Colorectal Carcinoma Post Aggressive Treatment	Hao Duan
SATURDAY	CMET-44	Predictors of Survival in Neuro-metastatic Merkel Cell Carcinoma	Maya Harary

FRIDAY	CMET-47	Clinical Evaluation of Fitness to Drive in Patients with Brain Metastases	Cristina Valencia-Sanchez
FRIDAY	COMP-01	Tracking Through Edema: Enhanced Neurosurgical Planning Using Advanced Diffusion Modeling of the Peritumoral Tissue Microstructure	Ragini Verma
FRIDAY	COMP-03	Tumor Connectome: Insight into the Impact of CNS Neoplasia and Therapy on the Brain Network	Ragini Verma
SATURDAY	COMP-04	R Tools for Exploratory Analysis of Publicly Available Data: Hpaanalyze and Beyond	Anh Tran
FRIDAY	COMP-05	Evaluation of a Deep Learning Architecture for MRI Prediction of IDH, 1p19q and TERT in Glioma Patients	Panagiotis Korfiatis
SATURDAY	COMP-08	Surviving by Exploring: Could Glioblastoma Cells Follow the Theory of Exploratory Adaptation?	Orieta Celiku
FRIDAY	COMP-09	HFE Expression Alters Outcomes in Brain Tumors	Darya Nesterova
SATURDAY	COMP-10	Anti-correlated Tgf&beta; And Alternative End-joining DNA Repair Signatures Associate with Outcome in Primary GBM	Mary Barcellos-Hoff
FRIDAY	COMP-11	Chromatin Run-on and Sequencing (ChRO-seq) Provides Retrospective Molecular Profiling and Transcriptional Activity of Brain Tumor Specimens Unsuitable for Conventional RNA Sequencing	Charles Danko
SATURDAY	COMP-12	Towards Big Data in Digital Neuropathology with the Digital Brain Tumor Atlas	Thomas Roetzer
FRIDAY	COMP-13	Silence of Hippo Pathway Induces Pro-tumoral Immunity: New Therapeutic Target of Glioblastomas	Eui Hyun Kim
FRIDAY	COMP-15	Meta-analysis of Cancer Cell Lines Based on Their Response to Tumor Treating Fields (TTFields)	Moshe Giladi
SATURDAY	COMP-16	Correlating MGMT Protein Level with Temozolomide Response in Glioblastoma Patients Using Mass Spectrometry	Dongyao Yan
FRIDAY	COMP-17	Binding Free Energy Analysis of Programmed Cell Death Protein PD1 to Its Ligand PD-L1	Peter Pan
SATURDAY	COMP-18	Machine Learning Differentiation Between Plexiform Neurofibromas and Malignant Nerve Sheath Tumors in Patients with Neurofibromatosis Type 1 (NF1) Based on MRI	Dafna Ben Bashat
FRIDAY	COMP-19	Water-content Based Electric Property Tomography (wEPT) for Modelling Delivery of Tumor Treating Fields to the Brain	Zeev Bomzon
SATURDAY	COMP-22	Large Scale Transcriptomic Analysis of Melanoma Brain Metastases	Soma Sengupta
FRIDAY	COMP-23	Assessment of Pituitary Adenoma Consistency and Vascularity Using Texture Analysis of Conventional MRI	Moran Artzi
FRIDAY	CSIG-01	Glycophosphatidylinositol Transamidase (GPIT) Subunit GPAA1 Is Overexpressed in Glioblastoma Multiforme (GBM) Cell Lines and Contributes to Tumor Cell Migration	Blake Johnson
SATURDAY	CSIG-02	VAL-083 Inhibits Proliferation of a Panel of Eight Glioblastoma Stem Cell Lines: Downregulation of BDR4 as a Novel Anti-neoplastic Mechanism	Elise Fernandez
FRIDAY	CSIG-03	Cyclic Depsipeptide Ligands to Target Co-translational Translocation and ER Proteostasis in Glioblastoma Cells	Jane Ishmael
SATURDAY	CSIG-04	A Requirement for RIOK2 Catalytic Activity in RTK-PI3K Dependent Glioblastoma	Nathaniel Boyd
FRIDAY	CSIG-05	PI3K Inhibitors PX-866 and BEZ235 Differentially Modulate Autophagy in GBM	Bryan Harder

FRIDAY	CSIG-07	Comparative Rna-seq Analysis of Gliomas of Different Malignancy Identifies Fyn as a Novel Regulator of Gbm Aggressiveness	Andrea Comba
SATURDAY	CSIG-08	Dynamics of Glioma Growth: Self-organization Guides the Patterning of the Extracellular Matrix and Regulates Tumor Progression	Andrea Comba
FRIDAY	CSIG-09	The Role of Hydrogen Sulphide in Gliomas	Farhana Akter
SATURDAY	CSIG-10	Investigating the S6K1 and S6K2 in Pten-deficient Glioblastoma	PRANJAL SARMA
FRIDAY	CSIG-11	Understanding the Mechanism of RIOK2 Function in Glioblastoma	Alexander Chen
SATURDAY	CSIG-12	Annexin A7 Isoforms Differentially Regulate Tumorigenic EGFR Signaling in Glioblastoma Multiforme	Sindhu Nair
FRIDAY	CSIG-13	Computational Modeling of Glioblastoma Stem Cell Signaling Networks	Brent Cochran
SATURDAY	CSIG-14	Alpha-cardiac Actin 1 Is Expressed in Medulloblastoma and May Play a Role in Cell Survival During Mitotic Inhibition	Roberto Diaz
FRIDAY	CSIG-15	SLFN5: A Repressor of Interferon-induced Signaling That Stimulates Glioblastoma Cell Proliferation. Survival Responses in Different Xenograft Glioblastoma Mouse Models	Frank D. Eckerdt
SATURDAY	CSIG-16	Intronic mir-744 Inhibits Glioblastoma Invasion Through Inhibition of MAPK-, SMAD- and Beta-catenin Signaling	Max Hübner
FRIDAY	CSIG-17	Characterization of an Alternatively Spliced NTRK2 Variant in Glioma: Employing Novel Reagents to Uncover Novel Functions	Siobhan Pattwell
SATURDAY	CSIG-18	Modeling Temozolomide Resistance with Glioblastoma Patient Derived Xenografts	C. David James
FRIDAY	CSIG-19	Detection of IDH1 R132H via Flow Cytometry in Intraoperative and Archival Glioma Specimens	Justine Sinnaeve
SATURDAY	CSIG-20	GBP2 Enhances Glioblastoma Invasion Through stat3/fibronectin Pathway	Ming Li
FRIDAY	CSIG-21	The Role of <i>mir-219a-2-3p</i> as a Tumor Suppressor in <i>idh1/2</i> -wild-type Grade II/III Gliomas	Jessica Fleming
SATURDAY	CSIG-22	Reconciling Tumor Heterogeneity in Glioblastoma Using a Pathway-based Approach	Alvaro Alvarado
FRIDAY	CSIG-23	mir-146a Predicts Better Overall Survival and Acts as a Temozolomide (TMZ) Sensitizer Through Targeting Multiple Signaling Pathways in Glioblastoma	Tiantian Cui
SATURDAY	CSIG-24	mir-575 Is Associated with Worse Survival of GBM Patients and Acts as a Novel Oncogene Through targeting <i>p27/cdkn1b</i> and <i>BLID/BRCC2</i>	Tiantian Cui
SATURDAY	CSIG-26	Molecular Determinants of Sensitivity to pi3k/akt/mTOR Pathway Inhibition in Glioblastoma	Caroline von Achenbach
FRIDAY	CSIG-27	Differential Elevation of TERT Activity and Sensitivity to Temozolomide by Type of TERT Mutation in MGMT Promoter-methylated Glioblastoma	Manuela Silgner
SATURDAY	CSIG-28	Long Noncoding RNA MIR22 Host Gene-derived mir-22-3p and mir-22-5p Promote Proliferation, Invasion and Self-renewal in Human Gliomas via Wnt/ $\beta$ -catenin Signaling	Mingzhi Han
FRIDAY	CSIG-29	The Dual pi3k/mTOR-pathway Inhibitor GDC-0084 Achieves Antitumor Activity in Breast Cancer Brain Metastases in vitro and in vivo	Franziska Ippen
SATURDAY	CSIG-30	Deubiquitinating Enzyme (USP5) Cooperate with RNA Binding Protein (hnRNPA1) During Glioma Progression, Bring Therapeutic Insights	Ajay Yadav
FRIDAY	CSIG-31	Mutation of PIM1 Gene in Primary Central Nervous System Lymphoma Inhibits Cell Death Through Change in Subcellular Localization of pim-1 and Increase of BAD Phosphorylation	Nobuyoshi Sasaki

SATURDAY	CSIG-32	Dual pi3k/akt Inhibition to Overcome the P-gp/bcrp Drug Efflux System for Improved Drug Delivery in Glioblastoma Therapy	Bjoern Bauer
FRIDAY	CSIG-33	Oncolytic Herpes Virus Treatment Induced NOTCH Signaling via HSV-1 Microrna H16 and It Involved in Treatment Resistance	Yoshihiro Otani
FRIDAY	CSIG-35	MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma	Tianzhi Huang
SATURDAY	CSIG-36	Involvement of Micrnas 221/222-3p in the Regulation of Programmed Cell Death 10 (PDCD10) Gene in Glioblastoma	Nargis Malik
SATURDAY	CSIG-38	robo2 Signaling in Invasion of Glioblastoma	Amber Kerstetter-Fogle
FRIDAY	CSIG-39	HIV-1 Envelope Protein gp120 Promotes Activation of Protein Synthesis in Gliomas Through the ERK and Akt Signaling	Lilia Kucheryavykh
FRIDAY	CSIG-41	Oncogene Addiction Switch from NOTCH to PI3K Require Simultaneous Targeting of Dual Pathway Inhibition in Glioblastoma	Norihiko Saito
SATURDAY	CSIG-44	Treatment with the Casein Kinase 2 Inhibitor, CX-4945, Sensitizes Medulloblastoma to Temozolomide	Ryan Nitta
FRIDAY	CSIG-45	Ranbpm as a Partner of STAT5 Regulates Ifn- $\lambda$ ; Signaling Pathway	Junwen Zhang
SATURDAY	CSIG-46	Development of a Novel Glioblastoma Model to Study the Role of NOX4 in Disease Pathogenesis	Levi Adams
SATURDAY	CSIG-48	Phosphorylation of EZH2 Promotes Glioblastoma Stem-like Cells Self-renewal Through Nf- $\kappa$ b Methylation	Chunyu Gu
FRIDAY	DDIS-01	The Antibody-drug Conjugate ABT-414 Demonstrates Single-agent Anti-cancer Activity Across a Panel of GBM Patient-derived Xenografts	Bianca Marin
FRIDAY	DDIS-03	EGFR Amplification Induced Increased DNA Damage Response and Predicted Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma Stem-like Cells	Shaofang Wu
FRIDAY	DDIS-05	Patient Derived Neurosphere Cultures Identify Novel Chemovulnerabilities in Glioblastoma	Darren Finlay
SATURDAY	DDIS-06	AAV Toolkit Enabling Precision Combinatorial Virotherapy for Glioblastoma	Hunter Futch
FRIDAY	DDIS-07	Msc-derived Exosomes and Microrna in Glioma Therapy	Irtiza Hasan
SATURDAY	DDIS-08	Development of Brain-penetrant EGFR Inhibitors for Glioblastoma	Jonathan Tsang
FRIDAY	DDIS-09	Identification of gsk3 $\beta$ ; Inhibitor Kenpaullone as a Temozolomide Enhancer Against Glioblastoma	Tomohiro Kitabayashi
SATURDAY	DDIS-10	Engineered Exosomes for Glioma Therapy	Anwar Hossain
FRIDAY	DDIS-11	A ck1a Activator Penetrates the Brain, and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma	Jezabel Rodriguez Blanco
SATURDAY	DDIS-12	ONC201: The First Selective, Non-competitive DRD2/3 Antagonist for Clinical Neuro-oncology	Joshua Allen
FRIDAY	DDIS-13	Understanding Glioblastoma Susceptibility to top2-targeting Drugs for Personalized Therapy	Adam Sonabend
SATURDAY	DDIS-14	Modified Carbazoles Destabilize Microtubules and Kill Glioblastoma Multiform Cells	Nephi Stella
FRIDAY	DDIS-15	A Novel Dopamine Receptor 3 Antagonist Inhibits the Growth of Primary and Temozolomide Resistant Glioblastoma Cells	Sarah Scott

SATURDAY	DDIS-16	ONC201 in Combination with Radiation Exhibits Synergistic Efficacy in High Grade Gliomas and Other Advanced Cancers	Rohinton Tarapore
FRIDAY	DDIS-17	Multi-level Drug Development Pipeline for the Discovery of Tumor Microtubule Targeting Drugs	Erik Jung
SATURDAY	DDIS-18	The Proteasome: Targeting the Nf-&kappa;b Pathway in the Treatment of Glioblastoma Multiforme	Jamal Mohamud
SATURDAY	DDIS-20	New a6k boron Drug Delivery System for Clinical Application of Boron Neutron Capture Therapy (BNCT)	Hiroyuki Michiue
FRIDAY	DDIS-21	KIF11 Inhibitors Filanesib and Ispinesib as Novel Agents for Meningioma Therapy	Gerhard Jungwirth
SATURDAY	DDIS-22	WSD0922: A BBB Penetrable EGFR/EGFRVIII Small Molecule for the Treatment of GBM and Metastatic CNS Tumor	wei zhong
FRIDAY	DDIS-23	Betulinic Acid Suppress Glioblastoma Cells Through Inhibition of Unfolded Protein Response	Wei-Lun Lo
SATURDAY	DDIS-26	BTP-7, a Novel Peptide for Therapeutic Targeting of Malignant Brain Tumors	Choi-Fong Cho
FRIDAY	DDIS-27	Combined Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) and Poly (ADP-ribose) Polymerase (PARP) Impairs Glioblastoma Cell Growth	Lee Hwang
SATURDAY	DDIS-28	Gene Therapy with ohsv-1 CD/5-FC Exhibit Enhanced Antitumor Efficacy in Glioma Cell Line and Intracranial Murine Glioma Model	Fusheng Liu
SATURDAY	DRES-04	Characterization of a Model of Temozolomide Resistance in Glioblastoma	Elizabeth Bering
FRIDAY	DRES-07	Defining the Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Egfr-driven Glioblastomas Using Integrated Kinome and Transcriptome Profiling	Abigail Shelton
FRIDAY	DRES-11	A Systems Approach for Determining the Mechanism of Resistance to Tumor Treating Fields in Glioblastoma	Dongjiang Chen
SATURDAY	DRES-12	Functional Genetic Approaches to Overcome Temozolomide Resistance in Glioblastoma	Massimo Squatrito
FRIDAY	DRES-13	VEGF Blockade Enhances T Regulatory Cell Function by Dysregulating Glutamate Transport in GBM	Yu Long
SATURDAY	DRES-14	Protein Aggregate Formation Predicts Clinical Responses to EGFR Tkis	Pim French
FRIDAY	DRES-15	GSK3 Beta and hnrpa1 (RNA Binding Protein) Cooperates with Cmyc Transcriptional Regulator, Antagonizes GSK3 Alpha Under Therapeutic Stress	Ajay Yadav
SATURDAY	DRES-16	Hypoxic Microenvironment Detected by FRP-170 PET May Induce the Expression of Drug Resistance Genes in the Patient with Glioblastoma	Tatsuya Abe
SATURDAY	DRES-18	sumo1 and Valosin-containing Protein Regulate Retinoid Receptor Protein Turnover– A Process Disrupted in Glioblastoma	Virginia Rodriguez
FRIDAY	DRES-19	The Mechanisms of Resistance to Temozolomide in Glioma Cells	Shigeo Ohba
SATURDAY	DRES-20	The TNF Receptor Family Member fn14 Is Highly Expressed in Recurrent Glioblastoma (GBM) and in GBM Patient-derived Xenografts with Acquired Temozolomide Resistance	David Hersh
FRIDAY	EPID-03	The Minority advantage:-disparities in Primary Brain Tumor Survival in Texas State 1995-2013	Solomon Ambe
FRIDAY	EPID-05	A Case Series of Metastatic Glioblastoma at Memorial Sloan Kettering Cancer Center	Evan Noch
SATURDAY	EPID-06	Racial Disparity in the Surgical Management of Skull Base Chondrosarcomas: A Surveillance, Epidemiology, and End Results (SEER) Analysis	Sanjay Dhawan

FRIDAY	EPID-07	Relationship Between Cognition, Speed of Presentation and Semantic Verbal Fluency Test in Patients with New Intra-cerebral Tumors	Robin Grant
FRIDAY	EPID-09	The Role of Gender Phenotype in Paediatric CNS Tumour Incidence and Survival	Ryan Mathew
SATURDAY	EPID-10	Tumors in the Cauda Equina: A SEER Analysis of Tumor Types and Predictors of Outcome	SAURAV DAS
FRIDAY	EPID-13	Anti-angiogenic Therapy for High-grade Glioma: A Meta-analysis	Malaka Ameratunga
SATURDAY	EPID-14	Echoes from the Past- an Historical Cohort Study of Low Dose Radiation for Tinea Capitis and Brain Tumor Incidence in Israel	Shlomit Yust Katz
SATURDAY	EPID-16	Considerations for a Surgical RCT in Low-grade Gliomas: A Survey	Alireza Mansouri
FRIDAY	EPID-17	PRIMARY LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM. Clinical and Therapeutic Experience	Alberto Gonzalez-Aguilar
SATURDAY	EPID-18	Malignant Primary Brain and Other Central Nervous System Tumours Diagnosed Among the Canadian Population from 2009 to 2013	Faith Davis
SATURDAY	EPID-19	Brainstem Obesity In pediatric Ganglioglioma	Pournima Navalkele
SATURDAY	EPID-20	The Survival Benefit of Valproic Acid in Glioblastoma Trends Away from Significance with Newer Studies: A Systematic Review and Meta-analysis	Victor Lu
FRIDAY	EPID-21	Prediagnostic Presentations of Glioma in Primary Care: A Case-control Study	Linda Dirven
SATURDAY	EPID-22	Racial and Ethnic Differences in Adult Glioma Incidence and Survival in the United States	Quinn Ostrom
FRIDAY	EPID-23	Prediagnostic presentations of glioma in primary care: a case-control study	Martin Taphoorn
FRIDAY	EXTH-01	Modeling the Safety of Topical Agents for Skin Toxicity Associated with Tumor Treating Fields Therapy in Glioblastoma	Mario Lacouture
SATURDAY	EXTH-02	Dual Drug Modified Nanovesicles for Enhancing the Therapeutic Efficacy of Doxorubicin Towards Glioblastoma and MPNST	A.B. Madhankumar
FRIDAY	EXTH-05	microrna-138 Suppresses Glioblastoma Proliferation and Sensitizes Chemotherapy Through Focal Adhesion Kinase Inactivation	Tae Jin Lee
SATURDAY	EXTH-06	cd38-targeted Therapy in Glioblastoma	Sonikpreet Aulakh
FRIDAY	EXTH-07	Design and Evaluation of WP1122, an Inhibitor of Glycolysis with Increased CNS Uptake	Waldemar Priebe
SATURDAY	EXTH-08	Mesenchymal Glioblastoma Constitutes a Major Cerna Signature in the Tgf- $\beta$ pathway	Chunsheng Kang
FRIDAY	EXTH-09	Dianhydrogalactitol (VAL-083) Has the Potential to Overcome Major Challenges in the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)	Sabine Mueller
SATURDAY	EXTH-10	A Versatile and Modular Targeted Nanoparticle Platform for Delivery of Combination Therapies to Adult and Pediatric CNS Tumors	Fred Lam
FRIDAY	EXTH-11	Glioblastoma Stem Cell Growth Dependence on Nutrients: More Than Basal Metabolic Activities	Chen Zhang
SATURDAY	EXTH-12	Effect of the Protein Arginine Methyltransferase PRMT5 Inhibition in Glioma Stem-like Cells	Sandeep Mittal
FRIDAY	EXTH-13	Reduction of Tumor Burden and Hearing Loss with a Multiple Receptor Tyrosine Kinase Inhibitor Brigatinib in a Genetically Engineered Mouse Model of Neurofibromatosis Type 2	Abbi Smith
SATURDAY	EXTH-14	Repurposing of Approved Drugs for the Treatment of Glioma Stem Cells	Sang Lee

FRIDAY	EXTH-15	Targeting Androgen Signaling in Glioblastoma (GBM) Using Seviteronel (SEVI), a CYP17 Lyase and Androgen Receptor (AR) Inhibitor, Alone and in Combination with Radiation (RT)	Daniel Wahl
SATURDAY	EXTH-16	GOLPH3 Sensitizes the Tumor Suppression Effect of Gefitinib on Gliomas	Xiuping Zhou
SATURDAY	EXTH-18	Development of Ultrasound-facilitated Drug Delivery Device for Local Drug Infusion Against Brain Tumors	Ryuta Saito
FRIDAY	EXTH-19	Wireless Intracranial Fluorescence Monitor for Drug Detection in Brain Tumor Patients	Herbert Engelhard
SATURDAY	EXTH-20	Histone Deacetylase Inhibitor Enhances Oncolytic Herpes Simplex Virus Therapy for Malignant Meningioma	Hiroaki Wakimoto
FRIDAY	EXTH-21	Repurposing Glioblastoma Exosomes as Personalized Multi-antigenic Anti-tumor Vaccine	Sophie Dusoswa
SATURDAY	EXTH-22	Verteporfin Treatment Inhibits GBM Growth and Migration and Informs Hippo/rtk Crosstalk	Anne Marie Barrette
SATURDAY	EXTH-24	Exposure to Tumor Treating Fields Inhibits DNA Repair, Induces Replication Stress and Renders Tumor Cells Sensitive to Agents That Impinge upon These Pathways	Michael Story
SATURDAY	EXTH-26	Molecular Determinant of Clinical Response to ONC201, an Inhibitor of Dopamine Receptor 2 (DRD2) Signaling, in Glioblastoma Patients	Clark Chen
SATURDAY	EXTH-28	Enhancing Selumetinib-mediated Killing of SHH Medulloblastoma	Brent Guppy
FRIDAY	EXTH-29	Multi-receptor Targeting in GBM	Puja Sharma
SATURDAY	EXTH-30	<i>in Situ</i> Autovaccination Mediated by Oncolytic Adenovirus delta-24-rgdox Induces Efficacious Immunity Against Metastatic Melanoma	Juan Fueyo
FRIDAY	EXTH-31	Targeting the Formin-directed Cytoskeleton with Small Molecule Agonists Blocks Glioblastoma Patient-derived Neurosphere Invasion	Kathryn Eisenmann
FRIDAY	EXTH-33	Comprehensive Targeting of Novel Master Regulators of Cancer Stem Cells to Treat Glioblastoma – <i>in vivo</i> Study	Changwang Deng
FRIDAY	EXTH-35	<i>In vivo</i> 1h MRS Detects Reduced 2HG Production in IDH1 Mutant Gliomas Treated with a Dual pi3k/mtor Inhibitor	Georgios Batsios
SATURDAY	EXTH-38	A New Computational Method for Comprehensive Estimation of Anti Tumor Efficacy of Tumor Treating Fields (TTFields). Accounting for Field Intensity, Exposure Time and Unwanted Spatial Field Correlation	Anders Korshoej
FRIDAY	EXTH-39	Detection, Molecular Profiling and Culture of Csf-ctcs in Leptomeningeal Disease (LMDz) in Melanoma to Improve Diagnosis and Treatment Strategies	Peter Forsyth
SATURDAY	EXTH-40	Optimizing Array Layouts for Glioblastoma Therapy with Tumor Treating Fields (TTFields) – use of Oblique Array Layouts Surpass Default Left-right/anterior-posterior Positions in a Computer Simulation Model	Anders Korshoej
FRIDAY	EXTH-41	Effects of Tumor Treating Fields (TTFields) on Blood Brain Barrier (BBB) Permeability	Almuth Kessler
SATURDAY	EXTH-42	Canscript May Predict a Subset of Glioblastomas That Respond to SP1 Blockers	Amitava Ray
SATURDAY	EXTH-44	Targeting Glioma Stem Cells with CAR-T Immunotherapy in Xenograft Animal Models	Mansour Gergi
FRIDAY	EXTH-45	The Repurposed CUSP9 Regimen Exerts Potent Anti-neoplastic Activity Against Glioblastoma Cells <i>in vitro</i>	Marc-Eric Halatsch
SATURDAY	EXTH-46	A Combinatory Immunotherapy Against Brain Tumour: Blood Dendritic Cell Based Vaccine Therapy with Checkpoint Inhibitor(s)	Julius Kim

FRIDAY	EXTH-47	Development of a Novel Fluorescent Virus-like-particles as RNA Interference and Tumor Suppressor Gene Delivery Tool for Brain Tumor Treatment	Chiungyin Huang
SATURDAY	EXTH-48	Oral Gallium Maltolate Impairs Tumor Growth and Extends Disease-specific Survival in a Xenograft Model of Recurrent GBM	Mona Al-Gizawiy
FRIDAY	EXTH-49	Novel Ad-reic Vector with the Super Gene Expression (SGE) System (Ad-SGE-REIC) as a Promising Therapeutic Agent for Malignant Glioma	Kazuhiko Kurozumi
SATURDAY	EXTH-50	Novel Iodine Nanoparticles (INPs) for Radiation Enhancement of Brain Tumors	James Hainfeld
FRIDAY	EXTH-51	c18-ceramide Analogue Drug Overcomes Resistance to Temozolomide in Glioblastoma	Arabinda Das
SATURDAY	EXTH-54	bcl-2/bcl-xl Inhibition Synergistically Enhances the Anti-neoplastic Activity of CUSP9 Against Glioblastoma Cells <i>in vitro</i>	Georg Karpel-Massler
FRIDAY	EXTH-55	Concomitant Inhibition of RAC1 and bcl-2/bcl-xl Interferes with the mcl-1/usp9x Axis and Yields Synergistic Anti-glioma Activity	Georg Karpel-Massler
SATURDAY	EXTH-56	Clinically Deliverable Deep Brain Stimulator Generated Electrical Fields Have Profound Effects on Glioblastoma Multiforme Cell Lines	Joshua Branter
FRIDAY	EXTH-57	Plasma and Cerebrospinal Fluid Pharmacokinetics of the Pro-caspase-activating Compound, PAC-1, Following Oral Administration in a Non-human Primate Model	Cynthia Lester McCully
SATURDAY	EXTH-58	ONC206, an Imipridone Family Member, Suppresses Glioblastoma Cells via Blocking Cancer Stemness Pathways	Jinkyu Jung
FRIDAY	EXTH-59	Intracranial Implantation of Tumoricidal Stem Cell-seeded Scaffolds After Glioblastoma Resection	Kevin Sheets
FRIDAY	EXTH-61	Partnership for Defining the Impact of 12 Select Rare CNS tumors: A Report from CBTRUS and the NCI-connect	Gabrielle Truitt
SATURDAY	EXTH-62	The Dielectric Properties of Malignant Glioma Tissue	Martin Proescholdt
FRIDAY	EXTH-65	BET Inhibition in Combination with Temozolomide Targets Mycn-positive Glioblastoma Cells	Matko Čančer
SATURDAY	EXTH-66	Elucidating the Translational Potential of Ia2o3 Nanoparticles as a Novel Therapy in Glioblastoma	Victor Lu
FRIDAY	EXTH-67	High-dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma <i>in vitro</i> and <i>in vivo</i> Compared with Monotherapy	Yong-Kil Hong
SATURDAY	EXTH-68	Zika Virus Oncotropism Towards Glioblastoma Progenitor Cells Is Mediated by the Tyrosine Kinase Receptor Axl	Richard Rovin
FRIDAY	EXTH-69	Magnetic Hyperthermia Therapy of Experimental Glioblastoma in Combination with Chemoradiation	Keon Mahmoudi
FRIDAY	EXTH-71	radiation-induced Targeted Nanoparticle-based Gene Delivery for Brain Tumors	Bakhos Tannous
SATURDAY	EXTH-72	Mp-pt(iv): A MAOB Sensitive Mitochondrial Smart Bomb for Treating Glioma	Martyn Sharpe
FRIDAY	EXTH-73	Targeting the Sweet-tooth of Glioma	Martyn Sharpe
SATURDAY	EXTH-74	Molecular Mechanisms of Anti-tumor Action of TTFIELDS Determined by Measurements and Modeling of Electro-conductive Properties of Microtubules	Jack Tuszynski
FRIDAY	EXTH-75	The Aurora Kinase A Inhibitor Alisertib Is Synergistic with Irinotecan and Carboplatin Against Glioblastoma Cells	Eric Burton
SATURDAY	EXTH-76	<sup>1</sup> H and Hyperpolarized <sup>13</sup> C MRS Biomarkers of IDH1 Mutant Glioma Response to Temozolomide Therapy	Elavarasan Subramani

FRIDAY	EXTH-77	PARP Inhibition Strikingly Enhances Chemotherapeutic Effect in Chordoma	Chunzhang Yang
SATURDAY	EXTH-78	PARP Inhibition Improves Radiotherapy Effectiveness in Meningioma Cell Culture	Randy Jensen
FRIDAY	EXTH-79	Bevacizumab, Irinotecan, Temozolomide, Tyrosine Kinase Inhibition, and MEK Inhibition Are Effective Against Pleomorphic Xanthoastrocytoma Regardless of V600E Status	Eric Thompson
FRIDAY	EXTH-81	Targeting nrf2 Antioxidative Pathway as a Novel Therapeutic Strategy for <i>idh1</i> -mutated Cancers	Chunzhang Yang
FRIDAY	GENE-03	Wild-type tp53 Undergoes a Cell Type-specific Inactivation by SIRT1 in <i>de novo</i> Glioblastoma	Sara Piccirillo
FRIDAY	GENE-05	Upregulation of odz1-mediated Invasion in the Hypoxic Tumor Microenvironment in Glioblastoma	Carlos Velásquez
FRIDAY	GENE-07	Genomic Enhancer Methylation Is Associated with Biological and Clinical Features in Pituitary Tumors	Maritza Mosella
SATURDAY	GENE-08	Schwannomatosis Schwannomas Harbor Distinct DNA Methylation Profiles	Sheila Mansouri
SATURDAY	GENE-10	Identification of MXRA5 and DSP as Relevant Targets in Infiltrating Astrocytomas: A Whole Exome Analysis at a Single Institution	Rohan Ramakrishna
FRIDAY	GENE-11	Small Terminal Alterations and Alternative Lengthening of Telomeres Are a Feature of <i>idh-mutant</i> , <i>1p/19q</i> Non-codeleted Gliomas	Desmond Brown
SATURDAY	GENE-12	Exploring the Micrnas That Regulate Pro-renin Receptor, the Key Molecular for Gliomagenesis	Daisuke Ogawa
SATURDAY	GENE-14	DNA Methylation and Proteomic Alterations Identify Histologically-defined Tumor Cell Populations and Characterize Intratumor Heterogeneity in Glioblastoma	Jean-Pierre Gagner
FRIDAY	GENE-15	Cell Autonomous Mechanisms of Sex Differences in Response to Tumor Suppressor Loss	Lauren Broestl
SATURDAY	GENE-16	Clinically Aggressive Meningiomas Are Characterized by Mutational Signatures Associated with Defective DNA Repair and Mutations in Chromatin Remodeling Genes	Sylvia Kurz
FRIDAY	GENE-17	TOP2B Regulates CDK4 Splice Variants in Gliomas	Edgar Gonzalez-Buendia
FRIDAY	GENE-19	Gaining a Better Understanding of DNA Methylation Features Associated with Sex Differences in Glioblastoma	Lindsay Stetson
SATURDAY	GENE-20	A Novel K-M Enhancer Regulates Temozolomide Resistance and Tumor Growth in Glioblastoma	Xiaoyue Chen
FRIDAY	GENE-21	A Common Fetal Developmental Origin for PFA Ependymoma, PFB Ependymoma, and Cerebellar Pilocytic Astrocytomas?	Maria Vladoiu
FRIDAY	GENE-23	Previously Identified Common Glioma Risk Snps Are Associated with Familial Glioma	Quinn Ostrom
SATURDAY	GENE-24	Impact of Therapy on Evolution of GBM	Astrid Wendler
FRIDAY	GENE-25	Loss of m6a RNA Methylation During Glioma Stem Cell Differentiation Is Regulated by Mirnas and Promotes Translation Efficiency	John Zepecki
FRIDAY	GENE-27	Genome-wide DNA Methylation Profiling in Grade II and III Gliomas Reveals a Subset of Genes with Prognostic Significance Controlled by Promoter Methylation	Wei Meng
FRIDAY	GENE-29	<i>dll3</i> and <i>etv1</i> are Inactivated/methylated in <i>cic</i> Wild-type, <i>idh</i> -mutated, <i>1p/19q</i> -codeleted Glioma	Matthew Kosel
SATURDAY	GENE-30	Increased Tumor Mutational Load After Radiotherapy and Temozolomide in Progressing Glioblastoma – a Prospective Study	Dorte Schou Nørøxe

FRIDAY	GENE-31	Multiplatform Molecular Profiling and Quantitative Imaging of an Anaplastic Ependymoma Reveals Intratumoral Heterogeneity	David Raleigh
SATURDAY	GENE-32	Association of Oligodendroglial Morphology, Molecular Factors and Overall Survival in Patients with Lower Grade Gliomas	Eriel Pareira
FRIDAY	GENE-33	Mechanism of Acquired Mutation After TMZ Treatment	Kuniaki Saito
SATURDAY	GENE-36	Aberrant Active-enhancers Associated with Downregulation of HDAC1-RET Finger Protein Complex Overcome Chemoresistance in Glioblastoma	Masaki Hirano
FRIDAY	GENE-37	ATRX Inactivation Disrupts Global Heterochromatin Landscapes and Alters Disease-relevant Transcriptional Activity	Carla Danussi
FRIDAY	GENE-39	Microrna-based Markers in Cerebrospinal Fluid as Potential Diagnostic Tools for Leptomeningeal Metastasis in Lung Adenocarcinoma Patients	Guozi Yang
SATURDAY	GENE-40	MEGF10, a Glioma Survival Associated Molecular Signature Predicts IDH Mutation Status	Guanzhang Li
FRIDAY	GENE-41	Liquid Biopsy Using Cell Free DNA from the Cerebrospinal Fluid (CSF) in Glioma	Jun-ichi Adachi
FRIDAY	HOUT-01	A Retrospective Analysis of Outcomes with Temozolomide as Initial Treatment of Grade 2 Oligodendroglioma	Amiee Maxwell
SATURDAY	HOUT-02	Variation in Post-operative Length of Stay in Neuro-oncologic Surgery	Saksham Gupta
SATURDAY	HOUT-04	Demographic Profiles, Management and Clinical Outcomes of Glioblastoma Patients Treated at St. Luke's Medical Center- philippines	Roy Allan Dominique Torcuator
FRIDAY	HOUT-05	Investigation of ki-67 Proliferative Index and Patient Survival in Glioblastoma Multiforme	Lakshmi Ravindra
SATURDAY	HOUT-06	Pattern of Low Field Intensity Recurrence in High-grade Gliomas Following Tumor Treatment Field Therapy	Robert Briggs
FRIDAY	HOUT-07	An Evaluation of the Treatment Course in Patients with Glioblastoma Multiforme	Alper Dincer
SATURDAY	HOUT-08	Comorbid Medical Conditions as Predictors of Overall Survival in Surgical Patients with Glioblastoma	Matthew Carr
FRIDAY	HOUT-09	Using the ASCO and ESMO Frameworks to Assess the Clinical Value of Tumor Treating Fields for Newly Diagnosed Glioblastoma Multiforme	Christina Proescholdt
SATURDAY	HOUT-10	Selective Serotonin Reuptake Inhibitor (SSRI) Treatment Is Associated with Improved Survival Among Elderly Patients Diagnosed with Glioblastoma	Sebastian Otto-Meyer
FRIDAY	HOUT-11	Economic Impact of Sodium Thiosulfate on Cisplatin-induced Hearing Loss	Rongwei (Rochelle) Fu
SATURDAY	HOUT-13	Postoperative Hearing Preservation in Patients Undergoing Retrosigmoid Craniotomy for Resection of Vestibular Schwannomas: A Meta-analysis of 1,249 Patients	Methma Udawatta
SATURDAY	HOUT-14	Homologous Recombination Deficiency in Patients with High Grade Gliomas	Matthew Krutz
FRIDAY	HOUT-15	Circulating Blood Cell Counts as Potential Biomarkers of Outcomes in Recurrent Glioblastoma Patients Treated with Bevacizumab	Eugene Vaios
FRIDAY	HOUT-17	Elderly Patients >65years of Age with Newly Diagnosed Glioblastoma Multiforme Gain Life Time from Treatment with Tumor Treating Fields and Temozolomide	Gregory Guzauskas
SATURDAY	HOUT-20	An Online Calculator for the Prediction of Survival and Adjuvant Treatment Benefit in Glioblastoma Patients	Joeky Senders
SATURDAY	HOUT-22	Two Case Reports of Patients with Superior Semicircular Canal Dehiscence and Ehlers-danlos Syndrome	Komal Preet

SATURDAY	HOUT-24	Duramatrix-onlay® Plus in Cranial Surgery Is Associated with an Acceptable Complication Profile: A Case Series	Methma Udawatta
FRIDAY	HOUT-25	Adherence to Tumor Treating Fields in Patients with High-grade Glioma – A Single Center Experience	Almuth Kessler
SATURDAY	HOUT-26	Survival Outcomes in Glioblastoma Patients Using TTFields: The Baylor Scott & White Medical Center in Central Texas Experience	Akhilesh Padhye
FRIDAY	HOUT-27	The Challenge of Health Utility Values for Glioblastoma Patients with Long-term Survival	Christina Proescholdt
SATURDAY	HOUT-28	Clinical Experience with Tumor Treating Fields (TTFields, Optune®) in Israel - Patient Acceptance and Safety	Tali Siegal
FRIDAY	HOUT-29	Healthcare Costs for High-grade Gliomas: A Population-based Study	Yang Liu
SATURDAY	HOUT-30	Tumor Treating Fields (TTFields) in Combination with Lomustine (CCNU) and Temozolomide (TMZ) in Patients with Newly Diagnosed Glioblastoma (GBM)	Martin Glas
FRIDAY	HOUT-31	Care Patterns and Treatment Efficacy: A Clinical Series of Primary Glioblastoma with an Emphasis on Older Adults	Meghan Hultman
SATURDAY	HOUT-32	Significance of Comorbidity Index in Elderly Patients with Glioblastoma	Masaki Okada
FRIDAY	HOUT-33	Functional Outcome of Glioma Surgery Under Awake Condition Aimed for Preservation of Several Functional Domains	Riho Nakajima
SATURDAY	HOUT-34	Adverse Events in Brain Tumor Surgery: Incidence, Type and Impact on Current Quality Metrics	Stephanie Schipmann
SATURDAY	HOUT-36	Institutional Compliance with Tumor Treating Fields for Glioblastoma	Robin Bonomi
FRIDAY	IMMU-03	Development of Cytomegalovirus (CMV) Based DNA Vaccines for GBM Using the UNITE Platform	Amit Adhikari
SATURDAY	IMMU-04	Overcoming Immune Evasion in Glioblastoma	Edbert Lu
FRIDAY	IMMU-05	Late Effects of Intracranial Radiation Induces Resistance to Immune Checkpoint Blockade Therapy That Is Partially Reversible with CSF-1R Inhibition	Tanner Johanns
FRIDAY	IMMU-07	Immune Profiles in the San Francisco Adult Glioma Study (AGS) Using Immunomethylomics	Annette Molinaro
SATURDAY	IMMU-08	The Role of WNT Signaling on T-cell Infiltration in Glioblastoma	Shweta Tiwary
FRIDAY	IMMU-09	Heterogeneous Intra-tumoral Antigen Expression in Relation to Immunotherapy of High Grade Glioma	Michael Barish
SATURDAY	IMMU-10	Radiotherapy and PD-1 Blockade Increases Tryptophan Metabolism in Brain Tumor-draining Secondary Lymphoid Organs	Rohan Savor
FRIDAY	IMMU-11	Identification of Glioma-associated Regulatory B Cells and Effects of Rituximab Immunotherapy	Catalina Lee Chang
SATURDAY	IMMU-12	Tgf&beta; Activation by Radiation Opposes Immune Rejection of Intracranial GL261	Mary Barcellos-Hoff
FRIDAY	IMMU-13	Effect of Combined anti-pd-1 and Temozolomide Therapy in Glioblastoma	Seok-Gu Kang
SATURDAY	IMMU-14	Therapeutic Modulation of the Phagocytic Axis Sparks Anti-tumor CD8 T Cell Responses in Glioblastoma	Christina von Roemeling
FRIDAY	IMMU-15	Engineered-drug Resistant Gamma-delta (&gamma;&delta;) T Cells Combined with Immune Checkpoint Blockade Augmented Killing of Cancer Cells	Sailesh Gopalakrishna Pillai

FRIDAY	IMMU-17	Peptide Vaccine Immunotherapy Biomarkers and Response Patterns in Pediatric Gliomas	Gary Kohanbash
SATURDAY	IMMU-18	Targeting the PD1 and TIGIT Checkpoint Pathways for Adult and Pediatric Gliomas	Gary Kohanbash
FRIDAY	IMMU-19	PD-1 Blockade Activates CD4 T Cells and the Innate Immune Response for Glioblastoma Eradication	Maria Carmela Speranza
SATURDAY	IMMU-22	Pharmacologically Targeting Extracellular Vesicle-immune Cell Interactions in Glioblastoma	Benjamin Himes
FRIDAY	IMMU-23	Antigen-specific Effector Memory CD4+ T Cells and CCL3 Potentiate Dendritic Cell Vaccines and Antitumor Immunity	Kristen Batich
SATURDAY	IMMU-24	The Impact of Brain Tumors on Hematopoietic Stem Cell-derived T Cells	Bayli DiVita Dean
FRIDAY	IMMU-29	Combination PD-1 Blockade and Irradiation of Brain Metastasis Induces an Effective Abscopal Effect in Melanoma	Lukas Pfannenstiel
SATURDAY	IMMU-30	High-dimensional Phenotyping of Immune Subsets and Checkpoints in the Mouse Glioblastoma Microenvironment	Matheus Crommentuijn
FRIDAY	IMMU-31	Dysfunctional STING Pathway Signaling Compromises Innate Immunity in Glioblastoma	Michelle Bowie
FRIDAY	IMMU-33	Targeted Immune Checkpoint Inhibitors for Intratumoral Delivery in GBM	Stephanie Sanders
FRIDAY	IMMU-35	Psychosocial Stress Negatively Impacts Immunotherapy in Immunocompetent Models of Glioblastoma	Erik Ladomersky
SATURDAY	IMMU-36	Immune Responses in Canine Gliomas Are Enriched at the Infiltrating Edge of Astrocytomas	Cynthia Kassab
FRIDAY	IMMU-37	Vemurafenib Enhances the Cytotoxicity of NY-ESO-1 TCR Engineered T-cells for BRAF Mutant Brain Tumors	Jacob Bethel
FRIDAY	IMMU-39	First-in-kind T Cells Carrying a Chimeric Antigen Receptor Against an Extracellular Matrix Protein Target Glioblastoma Cells and Show Anti-tumor Efficacy	Sadhak Sengupta
FRIDAY	IMMU-41	IDO1 Increases Treg Recruitment Independent of Tryptophan Metabolism in a Model of Glioblastoma	Lijie Zhai
SATURDAY	IMMU-42	TTFIELDS Induces Immunogenic Cell Death and STING Pathway Activation Through Cytoplasmic Double-stranded DNA in GBM	Dongjiang Chen
FRIDAY	IMMU-43	Rna-modified T Cells as a Non-invasive and Efficacious Strategy to Deliver Therapeutic Macromolecules Locally to Intracranial Tumors	Fernanda Pohl-Guimaraes
FRIDAY	IMMU-47	Harnessing Zika Virus (ZIKV) Oncolytic Activity in Brain Tumors	Arijita Jash
SATURDAY	IMMU-48	Glioma Immune Profiling Reveals Unique Immune Therapeutic Opportunities	Martina Ott
FRIDAY	IMMU-49	Cytotoxic T Cells and Their Activation Status Are Independent Prognostic Markers in Meningiomas	Christel Herold-Mende
FRIDAY	IMMU-51	The Combination of CCR2 Antagonist and PD-1 Blockade Prolongs Survival in Immune Checkpoint Inhibitor Resistant Gliomas	Joseph Flores-Toro
SATURDAY	IMMU-52	Tumor Treating Fields (TTFIELDS) Induce Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with anti-pd-1 Therapy	Tali Voloshin
FRIDAY	IMMU-53	Impact of Tumor-treating Fields (TTFIELDS) on the Immunogenicity of Glioma Cells	Manuela Silginer
SATURDAY	IMMU-54	The Oncometabolite r-2-hydroxyglutarate Suppresses the Innate Immune Microenvironment of idh1-mutated Gliomas via Aryl Hydrocarbon Receptor Signaling	Mirco Friedrich

FRIDAY	IMMU-57	Sequential Two-receptor Priming CAR System to Overcome Heterogeneous Antigen Expression	Payal Watchmaker
FRIDAY	IMMU-59	Detection of Human Cytomegalovirus Antigens in Malignant Gliomas as an Immunotherapeutic Target	Stephen Ahn
SATURDAY	IMMU-60	Mapping Tumoral and Immune Heterogeneity in PD-1 Responsive Glioblastoma	Bojan Losic
FRIDAY	IMMU-61	Inhibition of Mutant IDH1 with AGI-5198 Enhances the Efficacy of Radiotherapy Eliciting Immunological Memory and Improving Overall Survival	Padma Kadiyala
SATURDAY	IMMU-62	Low-grade Glioma Exclude CD8 T Cells, Which Is Accompanied by Low Expression of Chemo-attractants, Not Immunogenic Antigens	Bas Weenink
FRIDAY	IMMU-63	IDH1 Mutation Regulate Myeloid Cells Plasticity Mediating Anti-glioma Immunotherapy	Mahmoud Alghamri
SATURDAY	IMMU-64	A Decade of Research Targeting Immunosuppressive IDO1 in Glioblastoma: Nearing the Finish Line or Just Beginning the Marathon?	Derek Wainwright
FRIDAY	IMMU-65	IL-6 Drives Alternative Macrophage Activation and Immune Suppression in Glioblastoma Through $\text{ppar}\&\gamma;/\text{hif-2}\&\alpha;$	Yi Fan
SATURDAY	IMMU-66	A Novel Metabolite to Increase Efficacy of Cellular Immunotherapy in the Treatment of Glioblastoma	Farhad Dastmalchi
FRIDAY	IMMU-67	Personalized Tumor Mrna Loaded Lipid Nanoparticles Prime the Systemic and Intratumoral GBM Milieu for Response to Immunotherapy	Elias Sayour
SATURDAY	IMMU-68	Single-cell Proteomic Analysis of Immune Cell Response to Checkpoint Blockade Using 30-parameter Flow Cytometry	Amber Giles
FRIDAY	IMMU-69	Prognostic Implication of B-cell Infiltrate in Patients with Glioblastoma (GBM)	Jasmin Jo
SATURDAY	IMMU-72	Targeting Glioblastoma Stem Cells Using a Second-generation Egfrviii Specific Peptide Vaccine Strategy	Mario Fidanza
FRIDAY	IMMU-73	Glioma in Situ Vaccination with Cowpea Mosaic Virus Nanoparticles	Amber Kerstetter-Fogle
FRIDAY	INNV-01	PROTECT Study: PRO Phylactic Skin Toxicity Therapy with Clindamycin and Clobetasol or Skin Barrier in Glioblastoma Patients Treated with Tumor Treating Fields	Mario Lacouture
FRIDAY	INNV-03	Safety and Adverse Event Profile of Tumor Treating Fields Use in the EMEA Region – a Real-world Data Analysis	Martin Glas
SATURDAY	INNV-04	Safety and Adverse Event Profile of Tumor Treating Fields in Glioblastoma – a Global Post-market Surveillance Analysis	Uri Weinberg
SATURDAY	INNV-06	Factors Influencing Receptivity to Clinical Research in an Urban Neuro-oncology Practice	Mary Welch
FRIDAY	INNV-07	Brachytherapy in Glioblastoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis	Ali Alattar
SATURDAY	INNV-08	The Utilization of Intraoperative Confocal Laser Endomicroscopy During the Fluorescence Guided Surgery for Brain Tumors	Evgenii Belykh
FRIDAY	INNV-09	Pilot Study of a Smartphone-based Symptom Assessment (OurBrainBank) for Subjects with Glioblastomas	Fabio Iwamoto
SATURDAY	INNV-10	Peripheral Myeloid Cell pd-I1 Is a Biomarker for High-grade Intracranial Malignancy	Yuping Li
FRIDAY	INNV-11	The Honor Project: A Neuro-oncology Team Addresses Grief	Rosemary Rossi

SATURDAY	INNV-12	A Quality Improvement Program for Glioblastoma Patient Care Quality in Two Academic Tertiary U.S. Neuro-oncology Centers	Manmeet Ahluwalia
FRIDAY	INNV-13	ALLELE: A Consortium for Prospective Genomics and Functional Diagnostics to Guide Patient Care and Trial Analysis in Newly-diagnosed Glioblastoma	Mehdi Touat
FRIDAY	INNV-15	Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma	Nicholas Metrus
SATURDAY	INNV-16	Mirna Signature Derived from GBM Plasma Exosomes as a Diagnostic Biomarker	Luz Cumba Garcia
FRIDAY	INNV-17	Tumour Treating Fields: Acceptable to a UK Population?	Michael Jenkinson
SATURDAY	INNV-18	Caregiver Support in the Neuro-oncology Clinic; Ideas to Address the Needs of caregivers as Part of the Patient Careplan	Margaretta Page
FRIDAY	INNV-19	Plasma Extracellular Vesicle Glial Fibrillary Acidic Protein and Tau as Biomarkers for Brain Cancer	Ali Alattar
SATURDAY	INNV-20	Utility of Telehealth for Specialty Neurofibromatosis (NF) Care	Justin Jordan
FRIDAY	INNV-21	An Overview of Nigerian Neuro-oncology Scholarly Output	Adefisayo Adekanmbi
SATURDAY	INNV-22	Liquid Biopsy Detection of Genomic Alterations in Pediatric Brain Tumors from Cell Free DNA in Peripheral Blood, CSF, and Urine	Mélanie Pages
FRIDAY	INNV-23	Safety and Adverse Event Profile of Tumor Treating Fields in Elderly Patients – a Post-market Surveillance Analysis	Wenyin Shi
SATURDAY	INNV-24	Safety of Tumor Treating Fields in Glioblastoma Patients with Implanted Non-programmable and Programmable Shunts, and Pacemakers/defibrillators: 6.5-year Updated Retrospective Analysis	Yvonne Kew
FRIDAY	INNV-25	Improving Quality of Care of Meningioma Patients: Initial Evaluation of Issues in Care Trajectories According to the Plan-do-study-act Cycle	Amir Zamanipoor Najafabadi
SATURDAY	INNV-28	Extent of Resection in Newly Diagnosed Glioblastoma: Incorporating Clinical and Molecular Data to Predict Outcome	Julie Semenchuk
FRIDAY	INNV-29	Experience with TTFields (Optune®) in Pediatric High Grade Glioma Patients in Israel	Michal Yalon
SATURDAY	INNV-30	Tumor Treating Fields and Radiotherapy for Newly Diagnosed glioblastoma: Safety and Efficacy Results from a Pilot Study	Rachel Grossman
FRIDAY	INNV-31	User Experience with New, Aesthetically Improved Transducer Arrays for Delivery of Tumor Treating Fields for Glioblastoma	Adrian Kinzel
SATURDAY	INNV-32	Determination of Interleukin 10 in the Diagnosis of PCNSL	Enrique Gomez-Figueroa
FRIDAY	INNV-33	Implementation of Electronic Data Capture for Use in Natural History Studies: Utility of Center for Cancer Research's (CCR) Labmatrix and Scribe Systems for the Neuro-oncology Branch Natural History Study (NOB-NHS)	Elizabeth Vera
SATURDAY	INNV-34	Innovative, Independent, Patient Advocate Role Essential Throughout Drug Development in the Age of Social Media	Mary Lovely
FRIDAY	INNV-35	Routine Sequencing of Brain Tumors Uncovers High Rates of Actionable Opportunities: The UNC Experience	Simon Khagi
SATURDAY	INNV-36	A Metronomic Antiangiogenic Combination Therapy May Prolong Survival for Patients with Recurrent Medulloblastoma and Atypical Teratoid Rhabdoid Tumor	Irene Slavic

SATURDAY	INNV-38	The Neuro-oncology Branch Translational Research Immersion Program: Results from Two Years of Development and Participant Feedback	Amber Giles
FRIDAY	INNV-41	My STORI -- a Symptom Tracking and Reporting Instrument Mobile Application for Central Nervous System Cancer Patients	Xinyi Li
SATURDAY	INNV-42	Cost-effectiveness of Intraoperative MRI in the Treatment of High-grade Gliomas	Peter Abraham
FRIDAY	INNV-43	Nucleic Acid Adequacy from Archived Formalin-fixed Paraffin Embedded (FFPE) Tumor Tissue for Next-generation Sequencing (NGS) in National Cancer Institute (NCI)- natural History Study (NHS) of Primary CNS Tumor	Nicole Briceno
SATURDAY	INNV-44	Gram Positive Colonization of the Ommaya Reservoir; Treatment Recommendations with Clinical Examples	Christa Seligman APN
FRIDAY	INNV-45	RADIANS: A Multidisciplinary Central Nervous System Clinic Model for Radiation Oncology and Neurosurgery Practice	Shearwood McClelland III
SATURDAY	INNV-46	Evaluating the Decisions of Glioma Patients Regarding Clinical Trial Participation, a Retrospective Single Provider Study	Grant Jirka
FRIDAY	INNV-47	Treatment Allocation Among Patients Evaluated in a Multidisciplinary Radiation Oncology and Neurosurgery Central Nervous System Clinic	Shearwood McClelland III
SATURDAY	INNV-48	Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case	Shearwood McClelland III
FRIDAY	LTBK-03	Conventional and Advanced Imaging Findings Following Intracavitary Delivery of Autologous Chimeric Antigen Receptor T-cell Therapy in Recurrent Glioblastoma	Russell Rockne
FRIDAY	MNGI-02	Subcentimeter Meningiomas – Is It Okay to Ignore?	David Kamson
FRIDAY	MNGI-03	Patient Parameters Associated with Tumor Growth in Incidental Meningioma	David Kamson
FRIDAY	MNGI-04	A Proposed Imaging-based Nomenclature System for Meningiomas	Javier Villanueva-Meyer
FRIDAY	MNGI-06	Meningioma Metastases: Incidence and Screening in 1203 Patients	Cecilia Dalle Ore
FRIDAY	MNGI-08	A Rare Case of Infantile Papillary Rhabdoid Meningioma	Nabanita Bhunia
FRIDAY	MNGI-09	Fertility Treatment and Meningioma Incidence	Maryam Shahin
FRIDAY	MNGI-11	Longitudinal Genomic Analysis of Sporadic Meningiomas with Multiple Recurrences	Ghazaleh Tabatabai
FRIDAY	MNGI-13	A DNA Methylation-based Classifier for Assessment of Risk of Recurrence in Meningioma	Felix Sahn
FRIDAY	MNGI-15	Rare Presentation of Extracranial Paravertebral Meningioma in a Child with Neurofibromatosis Type 2: A Case Report	Magimairajan Issai Vanan
FRIDAY	MNGI-16	Treatment for Tuberculum Sellae Meningiomas: Endonasal Endoscopic Transsphenoidal versus Transcranial Surgery. a Meta-analysis of Comparative Cohort Studies	Boris Krischek
FRIDAY	MNGI-19	Surgical Resection of Spheno-orbital Meningiomas and Orbital Reconstruction Using Patient Specific CAD/CAM Implants	Boris Krischek
FRIDAY	MNGI-20	Large Peritumoral Edema Relative to Tumor Volume Predicts Secretory Subtype in Meningiomas	Niklas von Spreckelsen
FRIDAY	MNGI-21	Optimising Patient Selection for Antiepileptic Drug Therapy in Meningioma Surgery	Abdurrahman Islim
FRIDAY	MNGI-23	Preoperative Quantitative Imaging Features Are Prognostic for Meningioma Outcomes	David Raleigh

FRIDAY	MNGI-24	Predictors of Visual Outcomes in Spheno-orbital Meningioma Surgery Endorse Early Maximum Safe Surgery and Intensive Follow-up of Patients with Multiple Meningioma	Amir Zamanipoor Najafabadi
FRIDAY	MNGI-25	The Caregiver Burden in Meningioma: Long-term Results and Its Effects on Caregiver's Health-related Quality of Life, Anxiety and Depression	Amir Zamanipoor Najafabadi
FRIDAY	MNGI-26	The Disease Burden of Meningioma Patients: Long-term Results on Work Productivity and Healthcare Consumption	Amir Zamanipoor Najafabadi
FRIDAY	MNGI-29	Prognostic Value of <i>c-erbB2/her2</i> Expression in Human Meningiomas	Sverre Torp
FRIDAY	MNGI-30	Radiologic Features Are Prognostic for Clinical Outcomes of Chordoid Meningioma	David Raleigh
FRIDAY	MNGI-31	pfoxm1 Protein Expression in WHO Grade III Meningiomas Correlates with CDK4/6 Genotype and Transformation History	Michael Mooney
FRIDAY	MNGI-32	Long-term Cognitive Outcome of Meningioma and the Effects of Treatment (COMET) Study Results	Thomas Santarius
FRIDAY	MNGI-33	Results of Transcranial Resection of Olfactory Groove Meningiomas in Relation to Imaging-based Case Selection Criteria for the Endoscopic Approach	Thomas Santarius
FRIDAY	MNGI-34	The Role of Alanine as a Potential Metabolic Marker in Detecting Atypical Meningiomas	Kumar Pichumani
FRIDAY	MNGI-35	Simpson Grading Revisited: Surgeon's Estimation of Meningioma Removal vs. postoperative 68ga-dotatate PET/CT	Moritz Ueberschaer
FRIDAY	MNGI-38	Long-term Prognosis of Atypical and Malignant Meningioma : Outcome and Prognostic Factors	Sun-il Lee
FRIDAY	MNGI-40	Meningioma Resection Surgery in Elderly Patients: An Analysis of a National Database	Mina Lobbous
FRIDAY	MNGI-41	Large Volume Re-irradiation for Recurrent Meningioma with Pulsed Reduced Dose Rate Radiotherapy	Jacob Witt
FRIDAY	NCMP-01	Comparison and Quantitation of Histopathology Abnormalities in Surgically Resected Cerebral Radiation Necrosis as Compared with Recurrent Brain Tumor Following Radiation	Lisa Rogers
SATURDAY	NCMP-02	Multiple Sclerosis Outcomes After Cancer Immunotherapy	Catherine Garcia
FRIDAY	NCMP-05	Rituximab as initial therapy for the reversal of myasthenia gravis neurotoxicity caused by Ipilimumab/Nivolumab	Neha Verma
FRIDAY	NCMP-07	Clinical Neurological Features and Electrographic Patterns of Patients with Relapsed or Refractory Large B-cell Lymphoma Treated with Axicabtagene Ciloleucel at Memorial Sloan Kettering Cancer Center (MSKCC)	Alexandra Sequeira
SATURDAY	NCMP-08	Management of Radionecrosis After Stereotactic Radiation for Brain Metastases in the Setting of Immune Checkpoint Inhibitors	James Jurica
FRIDAY	NCMP-11	Neurodegeneration and "chemobrain": Predicting the Probability of Alzheimer's Disease in Breast Cancer Survivors	Rebecca Harrison
FRIDAY	NCMP-13	BDNF Enhancement via Ampakines as a Potential Treatment for Chemotherapy-related Cognitive Impairment	Naomi Lomeli
SATURDAY	NCMP-14	Treatment Response of Leptomeningeal Carcinomatosis in CLL: A Case Report and Review of the Literature	Alipi Naydenov
FRIDAY	NCMP-15	Postoperative Cerebellar Mutism Syndrome Following Treatment of Medulloblastoma: Neurological Characteristics and Severity by Molecular Subtype	Zsila Sadighi
SATURDAY	NCMP-16	Radiation Recall Myelitis Following Paclitaxel Chemotherapy in Metastatic Breast Cancer with Prior Spinal Stereotactic Body Radiotherapy: The First Reported Case	Shearwood McClelland III

FRIDAY	NCMP-17	Evolution of Cerebral Microbleeds After Proton Irradiation in Low-grade Glioma Patients	Thanakit Pongpitakmetha
SATURDAY	NCMP-18	Platelet Count Is Associated with Outcome in Cancer Patients Stroke	Bernardo Cacho-Diaz
FRIDAY	NCMP-19	Perioperative Seizure of Brain Tumor Surgery and Its Prevention. : A Single Institute Experience	Kanji Mori
SATURDAY	NCMP-20	Tumor Types, Resection and Incidence of Neuropathy: Current Literature Review	Sumul Raval
FRIDAY	NCMP-21	Real-world Surveillance Data for Tumor Treating Fields Affirm the Tolerability of Tumor Treating Fields for the Treatment of Glioblastoma in the United States	David Tran
FRIDAY	NCMP-23	Facial Palsy Induced by Cancer Immunotherapy: A Single Center Retrospective Study	Carlen Yuen
SATURDAY	NCMP-24	Brain-derived Circulating DNA as a Biomarker for Radiotherapy-induced Brain Damage	Chen Makranz
SATURDAY	NCMP-25	Seizure Incidence and Contributing Factors in Patients with Leptomeningeal Disease	Laura Zima
SATURDAY	NCMP-26	Stroke-like Migraine Attacks After Radiation Therapy Syndrome in Children with Cancer	Raja Khan
FRIDAY	NCMP-27	Quality of Life in Long-term Survivors of Pediatric Cancer: The Impact of Hearing Loss	Kristin Knight
SATURDAY	NCMP-28	PTPRZ1-MET Signaling Promotes Glioma Progression Through Stimulation the Transformation from M1 to M2 Macrophage	ZHAOSHI BAO
SATURDAY	NCMP-29	Cerebral Edema from Rapidly Progressive Metastatic CNS ATRT and Chemotherapy Induced Tumor Lysis	Pournima Navalkele
FRIDAY	NCMP-30	Outcome of Concomitant Chemoradiation with Temozolomide Followed by Temozolomide in Patients with Glioblastoma Multiforme	adeeba zaki
FRIDAY	NCMP-31	Risk of Intracranial Hemorrhage (ICH) in Patients with High-grade Glioma (HGG) on Therapeutic Low Molecular Weight Heparin (LMWH)	Jasmin Jo
SATURDAY	NCMP-32	Outcomes and Predictive Factors of Recraniotomy for Severe Complications Following Selective Craniotomy for Intracranial Tumors	Yong Liu
SATURDAY	NCOG-02	Longitudinal and Prospective Neurobehavioral Outcomes in Newly-diagnosed Primary CNS Lymphoma Patients Treated with Primary Cranial Radiotherapy Combined with or Without Mtx-based Chemotherapy	Shinn-Yn Lin
FRIDAY	NCOG-03	Indication of Awake Surgery for the Patients with Glioblastoma from the View Point of Functional Independence in the Chronic Phase	Mitsutoshi Nakada
FRIDAY	NCOG-05	Intra-individual Neurocognitive Variability in Patients with Cancer: A Predictor and Marker of Neurotoxicity Associated with Chemotherapy?	David Sheppard
SATURDAY	NCOG-06	Predicting Tumor Treating Field Compliance Using Neurocognitive Testing	Kaitlin Qualls
FRIDAY	NCOG-07	Neurocognitive Evaluation in Elderly Malignant Glioma Patients	Andrea Pace
SATURDAY	NCOG-08	Determining the Content Validity of Measures of Basic and Instrumental Activities of Daily Living (ADL) in Patients with Brain Tumors: A Systematic Review	Quirien Oort
SATURDAY	NCOG-10	Executive Dysfunction in Neurooncology: Behavior Rating Inventory of Executive Function in Adult Primary Brain Tumor Patients	Sarah Braun
FRIDAY	NCOG-11	Feasibility and Efficacy of an Ipad-based Cognitive Rehabilitation Program in Brain Tumor Patients	Jennie Taylor
SATURDAY	NCOG-12	Comprehensive Geriatric Assessment (CGA) for Outcome Prediction in Elderly Patients (PTS)with Glioblastoma (GBM): A Mono-institutional Experience	Giuseppe Lombardi

FRIDAY	NCOG-13	Neurocognitive Evaluation of Brain Metastases Patients Treated with Post-resection Stereotactic Radiosurgery: A Prospective Single Arm Clinical Trial	Andrew Kanner
SATURDAY	NCOG-14	Hippocampal N-acetylaspartate Concentration Correlates to Verbal Memory Before Radiotherapy for Brain Metastases	Radim Jancalek
FRIDAY	NIMG-01	A Blinded Image Evaluation Study to Determine the Diagnostic Efficacy of 18f-fluciclovine PET, as an Adjunct to MRI Imaging, in Adults with Glioma	Matthew Miller
SATURDAY	NIMG-02	Strain Elastography: Intra-operative Brain Tumour Carachterization	Francesco Prada
FRIDAY	NIMG-03	Radiomic Texture Analysis to Predict Response to Immunotherapy	Rivka Colen
SATURDAY	NIMG-04	Diffusion Restriction on MR Imaging in the T2 Hyperintense, but Otherwise Normal-appearing White Matter of Glioblastoma Patients Treated with TTFIELDS Correlates with Survival	Josef Vymazal
FRIDAY	NIMG-07	Deep Learning Detects Differences in the Mris of Male and Female Gliomas	Kyle Singleton
SATURDAY	NIMG-08	Reproducibility of Hyperpolarized C-13 Metabolic Imaging in Patients with Glioma	Adam Autry
FRIDAY	NIMG-09	iprompt: integrated predictive radiographic Biomarkers of progressed High Grade Astrocytic tumors	Na Tosha Gatson
FRIDAY	NIMG-11	Differentiating Treatment-induced Effects from True Recurrent High Grade Glioma Using Multiparametric MRI Techniques	Julia Cluceru
SATURDAY	NIMG-12	Radiogenomics on Venus and Mars: Impact of Sex-differences on MRI and Genetic Correlations in Glioblastoma	Leland Hu
FRIDAY	NIMG-13	Segmentation and Volumetric Analysis Improves Detection of Progression in Low Grade Gliomas	Hassan Fathallah-Shaykh
SATURDAY	NIMG-14	Multiregional Radiomics Profiling from Multiparametric MRI: Identifying an Imaging Predictor of IDH1 Mutation Status in Glioblastoma Multiforme	Yin-sheng Chen
FRIDAY	NIMG-15	Differentiation of IDH1 Mutant and Wild Type Gliomas Using Ph- and Oxygen-sensitive Molecular MRI	Jingwen Yao
SATURDAY	NIMG-16	Impact of Sex Differences and Tumor Location on Survival Outcomes in Glioblastoma Patients	Julia Lorence
FRIDAY	NIMG-17	Utilizing Machine Learning for Predictive Modeling of Seizure Presentation in Glioma Patients	Aditya Khurana
FRIDAY	NIMG-19	Sex-specific Brain Maps for Risk of Seizure Among Glioma Patients	Sara Ranjbar
SATURDAY	NIMG-20	Diffusion-weighted Magnetic Resonance Imaging Findings in Patients with Central Nervous System Involvement of Systemic Lymphoma	Ashley Roque
FRIDAY	NIMG-21	Sex Differences in Extreme Survivorship Among Primary Glioblastoma Patients	Paula Whitmire
SATURDAY	NIMG-24	Diffusion MRI Precursors to Progression in Grade II and III Glioma	Tracy Luks
FRIDAY	NIMG-25	Molecular Physiology of Contrast Enhancement in Glioblastomas: An Analysis of the Cancer Imaging Archive (TCIA)	Ali Alattar
FRIDAY	NIMG-29	In Silico Brain Tumor Models for Validating New Dynamic MR Imaging Methods Prior to Clinical Trials	Junzhou Chen
FRIDAY	NIMG-31	Breast Cancer Subtype as a Determinant of the Intracranial Metastases Location	Heba Fouad
SATURDAY	NIMG-32	Comparison of l-methyl-11c-methionine Positron Emission Tomography with Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma	Sied Kebir

SATURDAY	NIMG-34	The Impact of Tumor Treating Fields (TTFields) on Brain Anatomy Using Computational Anatomy Analysis	Andreas Hottinger
FRIDAY	NIMG-35	Treatment Response Assessment Maps (TRAMs) Sensitivity to Tumor/treatment-effects as a Function of Data Acquisition Parameters	David Guez
SATURDAY	NIMG-36	The Significance of Punctate Contrast-enhancing Lesions in Treated High Grade Glioma	Deborah Blumenthal
FRIDAY	NIMG-37	Association Between Metabolic Parameters from Dynamic 18FMC PET, Pharmacokinetic DCE-MRI Parameters, MRS Choline to Creatine Ratios and Tissue Immunohistochemistry for Choline Kinase Alpha Expression in Human Brain Glioma	Matthew Grech-Sollars
SATURDAY	NIMG-38	Quantitative Imaging Predictors of Overall Survival in Glioblastoma Patients Robust in the Presence of Inter-scanner Variations	Saima Rathore
FRIDAY	NIMG-39	The Evaluation of Diffusion Tensor Tractography Using Mixed Reality Integrated Virtual Space and Real Space	Tsukasa Koike
FRIDAY	NIMG-41	Non-invasive Detection of <i>idh</i> -wildtype Genotype in Gliomas Using Dynamic 18f-fet-pet	Bogdana Suchorska
SATURDAY	NIMG-42	Incidence of Cavernomatous Lesions on Brain MR of Pediatric Patients Treated with Intraventricular Radioimmunotherapy	GURCHARANJEET KAUR
FRIDAY	NIMG-43	Radiological Characteristics and Natural History of Adult IDH Wild-type Astrocytomas with TERT Promoter Mutations	François Ducray
SATURDAY	NIMG-44	Quantitative Multi-parametric Image Profiling Reveals Remarkable Heterogeneity Within <i>idh</i> -wildtype Glioblastoma, Offering Prognostic Stratification Beyond Current WHO Classifications	MacLean Nasrallah
SATURDAY	NIMG-46	Longitudinal Resting-state Functional Connectivity Confirms Marizomib (MRZ) Crosses the Blood Brain Barrier (BBB) and Correlates with Hallucination Severity in Recurrent GBM Patients	Daniela A. Bota
FRIDAY	NIMG-47	A Histogram-based, Back-projection Method for Treatment Response Assessment in Glioblastoma Using Multi B-value Advanced Diffusion MRI	Shah Islam
SATURDAY	NIMG-48	Volumetric Response to TTFields in Newly Diagnosed GBM	Christian Freyschlag
FRIDAY	NIMG-49	Electric Field Intensities Delivered by Tumor-treating Fields (TTFields) to Glioblastoma Regions: Effect on Treatment Response Assessed by Amino Acid PET	Csaba Juhasz
SATURDAY	NIMG-50	Growth Pattern and Prognostic Factors of Untreated Nonfunctioning Pituitary Adenomas	Kyeong-O Go
FRIDAY	NIMG-51	The Impact of Functional Magnetic Resonance Imaging on Clinical Outcomes in a Propensity-matched Low Grade Glioma Cohort	Joseph Megyesi
SATURDAY	NIMG-52	Prediction of Survival Outcome with Radiological Phenotypes in Idh-wild Type Lower Grade Gliomas Based on Machine Learning	Sung Soo Ahn
FRIDAY	NIMG-53	Repeatability of o-(2-18f-fluoroethyl)-l-tyrosine Positron Emission Tomography (FET-PET) Scanning and the Influence of Protein Intake in Glioma	Sarah Chehri
SATURDAY	NIMG-54	Spatial Distribution Atlases of Post-treatment MRI Scans Reveal Distinct Hemispheric Distribution of Glioblastoma Recurrence from Pseudo-progression	Marwa Ismail
FRIDAY	NIMG-55	Radiomics Analysis for Detection of IDH Mutation of Glioma Using Diffusion Tensor and Kurtosis Images	Satoshi Takahashi
SATURDAY	NIMG-56	Predictive Markers for MGMT Promoter Methylation in Glioblastomas	Tokunori Kanazawa
FRIDAY	NIMG-57	Imaging Features of Polymorphous Low-grade Neuroepithelial Tumor of the Young (PLNTY)	Derek Johnson

FRIDAY	NIMG-59	Validation of Quantitative Vessel Size Imaging (VSI) in Human Gliomas Using Image-guided Stereotactic Biopsies	Ararat Chakhoyan
SATURDAY	NIMG-60	Automatic Detection of High Amino Acid Uptake Regions in Glioblastoma from Multi-modal MRI: A Full 3D U-net Study of Deeply Learned PET Data	Csaba Juhasz
FRIDAY	NIMG-61	Management of Intraoperative MRI and Neuronavigation System with PET for Malignant Gliomas Management of Intraoperative MRI and Neuronavigation System with PET for Malignant Gliomas	Keisuke Miyake
FRIDAY	NIMG-63	Advanced Imaging for Assessing Volumetric Responses in Brain Metastases Treated with Checkpoint Blockade	Elizabeth Gerstner
SATURDAY	NIMG-64	A Clinical Rule for Preoperative Prediction of <i>braf</i> Mutation Status in Craniopharyngiomas	Shingo Fujio
FRIDAY	NIMG-65	Volumetric Assessment of Peritumoral Edema : Excellent Tool for Differential Diagnosis of Cerebral Gliomas and Solitary Metastases	Jeong Hoon Kim
SATURDAY	NIMG-66	Comparison of Steady State and Dynamic Brain Metabolism by Using 1H MRSI and Hyperpolarized [1-13c]pyruvate Imaging in Patients with Glioma	Yan Li
FRIDAY	NIMG-67	Clinical Applications of Quantitative Three-dimensional MRI Analysis for Pediatric Embryonal Brain Tumors	David Raleigh
FRIDAY	NIMG-69	Changes in Signal Intensity Ratios of Globus Pallidus and Dentate Nucleus on Unenhanced t1-weighted Images After Multiple Administrations of Macrocyclic Gadolinium-based Contrast Agents in Brain Tumor Patients	Tali Siegal
SATURDAY	NIMG-70	Quantitative Image Analysis and Machine Learning Techniques for Distinguishing True Progression from Pseudoprogression in Patients with Glioblastoma	Hamed Akbari
SATURDAY	NIMG-72	A Novel Array Layout for Delivering TFields to the Whole Brain	Zeev Bomzon
SATURDAY	NIMG-76	Post-gadolinium 3-dimensional Spatial, Surface, and Structural Characteristics of Glioblastomas Differentiate Pseudoprogression from True Tumor Progression	Madison Hansen
FRIDAY	NIMG-77	Multimodal Imaging of Glioblastoma Subregions: Impact on Overall Survival	Flora John
SATURDAY	NIMG-78	Evaluation of Ischemic Complications in Removal of Glial Tumor	Tadashi Higuchi
SATURDAY	NIMG-80	A Radiomic Signature as a Non-invasive Predictor of Progression-free Survival in Patients with Lower-grade Gliomas	Yinyan Wang
FRIDAY	PATH-01	Development of a Sensitive Multiplex Assay for Detection of Mutations in IDH1 and IDH2	Anjen Chenn
SATURDAY	PATH-02	Association of IDH1 Mutation with Histological Type in Indonesian Glioma	Rusdy Malueka
FRIDAY	PATH-03	Prognostic Importance of Tumor Grade in the Post-genomic Era	Rushikesh Joshi
SATURDAY	PATH-04	MDM2/4 Amplification and Risk of Hyperprogression in High-grade Gliomas Treated with Checkpoint Inhibitors	Laura Donovan
FRIDAY	PATH-05	Implementation of a Targeted Next-generation Sequencing Panel for the Diagnosis and Precision Medicine Treatment of Adult Patients with WHO Grade IV Diffuse Gliomas	David Solomon
SATURDAY	PATH-06	Quantitative Analysis of MGMT Promoter Methylation and Its Prognostic Value in Glioblastoma Multiforme (GBM) Patients Treated with Alkylating Chemotherapy- preliminary Report	Xiao-Tang Kong
FRIDAY	PATH-07	Proneural Gliomas Are Associated with Poor Survival and More Likely Located in Proximity to the Sub-ventricular Zone	Rushikesh Joshi

SATURDAY	PATH-08	The Ivy Glioblastoma Patient Atlas - A Novel Clinical and Radio-genomics Resource for Early Phase Clinical Trial Design and Interpretation	Keith Ligon
FRIDAY	PATH-09	Clinical Characteristics of Adults with H3 k27m-mutant Gliomas at UCSF	Robin Buerki
SATURDAY	PATH-10	Copy Number (CN)/single Nucleotide Polymorphism (SNP) Microarray Analysis of the <i>egfr</i> Locus in Gliosarcoma	Lindsey Lowder
FRIDAY	PATH-11	Translating Genomic Data of Glioblastoma into Clinical Practice: A Case Study	Toni Rose Jue
SATURDAY	PATH-12	Characteristics of Giant Cell Morphology in Long-term Survivors of Glioblastoma: Consideration of Sex Differences	Sandra Johnston
SATURDAY	PATH-14	Surgical Strategy for Lower Grade Gliomas Using Intraoperative Rapid Molecular and Pathological Diagnosis	Masayuki Nitta
FRIDAY	PATH-15	Microglia/macrophages Are the Major Tumor-associated Immune Cells in Pilocytic Astrocytoma	Jie Chen
FRIDAY	PATH-17	Increasing Value of Autopsies in Patients with Brain Tumors in the Molecular Era	Jared Ahrendsen
SATURDAY	PATH-18	Subclassification of Low-grade Gliomas Considering TERT Promoter Mutation and ATRX Loss: Beyond the 2016 WHO Classification	Jong Hee Chang
FRIDAY	PATH-19	Clinicopathologic Features and Outcomes of Histologically Confirmed Atypical Diffuse Intrinsic Pontine Glioma	Alexander Diaz
SATURDAY	PATH-20	Anaplastic Astrocytoma: Why Does Survival Differ so Much for the Same Histological Grade?	Edward Goacher
FRIDAY	PATH-21	Angiotensinogen Gene Silencing Predicts Bevacizumab Response in Recurrent Glioblastoma Patients	Hans Poulsen
SATURDAY	PATH-22	The Development of a New Assay to Measure 2-hydroxyglutarate (2-hg) Enantiomer Levels and the Utility of 2-hg as a Biomarker for Management of IDH Mutant Gliomas	Shinji Strain
FRIDAY	PATH-23	Germline <i>gnas</i> Mutation in an 18-month-old with Medulloblastoma	Jacquelyn Crane
SATURDAY	PATH-24	Recurrent Unusual Patterns in Clinical Molecular Profiling of Adult Diffuse Gliomas	Cristiane Ida
SATURDAY	PATH-26	Neuro-oncology Next-generation Sequencing 219-gene Panel for Comprehensive Clinical Testing	Cristiane Ida
FRIDAY	PATH-27	Identifying the Genetic Signature of Response in a Phase II Study of Tumor Treating Fields in Recurrent Glioblastoma	David Tran
SATURDAY	PATH-28	The Natural History of <i>braf v600e</i> -mutated Glioblastomas in Adults	Karisa Schreck
SATURDAY	PATH-30	Reconsideration for Poor Prognosis Oligodendroglial Tumor Cases Based on WHO2007 and WHO 2016	Takashi Maruyama
FRIDAY	PATH-33	Hexokinase 2 Knockout via CRISPR Reduces Downstream Gene Expression, Implicating a Reduction in Cell Proliferation and Drug Resistance	Daniel Blakeway
SATURDAY	PATH-34	Ventricular-subventricular Zone Contact by Glioblastoma Is Not Associated with Molecular Signatures in Bulk Tumor Data	Akshikumar Mistry
FRIDAY	PATH-35	Frequency and Characteristics of h3k27m-mutation in Adults with Radiographically-determined Midline Gliomas	Karisa Schreck
SATURDAY	PATH-36	IDH and TERT Promoter Mutations in Non-diagnostic Biopsies from Glioma Patients	Francois Ducray
SATURDAY	PATH-38	Correlation of Alteration of HLA-F Expression and Clinical Characterization in 593 Brain Glioma Samples	Gan You

FRIDAY	PATH-39	Astrocytoma of the Spinal Cord: A Genetic Characterization After Microsurgical Resection	Annamaria Biczok
SATURDAY	PATH-40	Targeted Next Generation Sequencing (NGS) of Young Adults with Isocitrate-dehydrogenase Wild-type Glioblastoma (IDH-WT GBM) Reveals Negative Prognostic Impact of Epidermal Growth Factor Receptor Amplification (EGFRamp)	Daniel Hoffman
FRIDAY	PATH-41	Plasma Cell-free DNA (cfDNA) Concentration Is Independently Associated with Radiographic Tumor Burden in Newly Diagnosed Glioblastoma (GBM) Prior to Initial Surgical Resection	Stephen Bagley
FRIDAY	PATH-43	Retrospective Reclassification of Adult Gliomas from a Manitoba Patient Cohort According to the WHO 2016 Guidelines	Amy Norquay
SATURDAY	PATH-44	The Landscape of Somatic Mutations and Copy Number Alterations in Primary Glioblastoma in Japan	Toru Umehara
SATURDAY	PATH-46	Neuronal Differentiation Is Induced by gli3 in WNT- and Shh-activated Medulloblastoma	Manabu Natsumeda
SATURDAY	PATH-48	Fusion Testing in Adult versus Pediatric Low and High Grade Brain Tumors for Eligibility for Trials	David Ormond
SATURDAY	PATH-50	High Detection Rate of <i>myd88</i> mutations in Cerebrospinal Fluid from Patients with Central Nervous System Lymphomas	Jun Watanabe
FRIDAY	PATH-51	DNA Copy Number Profiling Across Glioblastoma Populations Has Implications for Clinical Trial Design	P.J. Cimino
SATURDAY	PATH-52	Utilizing Next Generation Sequencing Reports in Clinical Decision Making: Report from the National Institutes of Health (NIH) Neuro-oncology Branch (NOB) Natural History Study (NHS) Primary Brain Tumor Panel (PBTP)	Christine Siegel
FRIDAY	PATH-53	Cerebrospinal Fluid Target Deep Sequencing Implicates an Alternative Assay of Glioblastomas Driver Genes in the Clinical Settings	Zhenqiang He
SATURDAY	PATH-54	Utility of Next Generation Sequencing in Adult Primary Brain Tumors: Impact on Diagnosis and Personalized Therapy	Matthew Smith-Cohn
FRIDAY	PATH-55	Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated with IMRT	Philip Sutera
SATURDAY	PATH-56	CHEK2 Mutation in High-risk Medulloblastoma	Nidhi Shah
FRIDAY	PATH-57	Molecular Determinants of Recurrence and Malignant Transformation in Diffuse Low Grade Glioma	Ko-Ting Chen
SATURDAY	PATH-58	Mismatch Repair Deficiency (MMRd) in Glioma Patients (PTS): Frequency and Correlation with Clinical, Histological and Molecular Characteristics	Giuseppe Lombardi
FRIDAY	PATH-59	Thalamic Gliomas with H3 K27M Mutation. a Case Series and Literature Review	Divya Mella
SATURDAY	PATH-60	Bioinformatic Profiling Identifies the Secreted Glycoprotein ADAMTSL4 to Be a Potential Novel Immune-related Biomarker for Primary Glioblastoma	Kenan Zhang
FRIDAY	PATH-61	A Novel Analysis Model of <i>mgmt</i> methylation Pyrosequencing Offers an Optimal Predictive Performance in Gliomas	Ruichao Chai
SATURDAY	PDCT-02	Combined Inhibition of mtorc1/c2 and MEK Pathway Is Synergistic in Preclinical Testing of Pediatric Low-grade Glioma Including a Novel Patient-derived NF1 Pilocytic Astrocytoma Cell Line	Antje Arnold
FRIDAY	PDCT-03	A Phase II Trial of Poly-iclc in the Management of Recurrent or Progressive Pediatric Low Grade Gliomas. Results for The Neurofibromatosis 1 Group. (NCT01188096)	Dolly Aguilera

FRIDAY	PDCT-05	Feasibility of Prospective Whole-exome Sequencing (WES) in Pediatric Medulloblastoma Patients on the Head Start 4 Protocol	Richard Graham
FRIDAY	PDCT-07	Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma: A Pediatric Brain Tumor Consortium Study	Eugene Hwang
FRIDAY	PDCT-11	Surveillance Data Demonstrates the Tolerability of Tumor Treating Fields in Pediatric Glioma Patients	Derek Hanson
SATURDAY	PDCT-12	A Phase I Trial of Tumor Treating Fields with and Without Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma and Ependymoma	Derek Hanson
FRIDAY	PDCT-13	Pineoblastoma in Children: The Head Start Experience	Mohamed AbdelBaki
FRIDAY	PDTM-01	Germline Genetic Predisposition to Pediatric Glioma	Ivo Muskens
SATURDAY	PDTM-02	Stress Granules Are Induced by Oxidative Stress in Pediatric Brain Tumors and Predict Poor Outcome	Alberto Delaidelli
FRIDAY	PDTM-03	Credentialing Novel Pediatric Glioma Models	Joshua Breunig
SATURDAY	PDTM-04	Therapeutic Modulation of Cholesterol Homeostasis in DIPG Through Massive Generation of 24,25-epoxycholesterol	Richard Phillips
FRIDAY	PDTM-07	Detection of IDH1 R132H Mosaicism in Anaplastic Astrocytoma Patients	Sulgi Lee
FRIDAY	PDTM-08	Role of mir-212 as a Tumor Suppressor Gene in Non-shh/wnt Medulloblastoma	Naveen Perumal
FRIDAY	PDTM-09	Diffuse Intrinsic Pontine Glioma and Pediatric Glioblastoma Derived-exosomes Have Specific Oncogenic Signatures	Maria Vinci
SATURDAY	PDTM-10	Novel Rna-targeting Strategy for Treating T Cell-driven Immunosuppression in Human Diffuse Intrinsic Pontine Glioma	Alicia Lenzen
FRIDAY	PDTM-14	mir-1253 Is a Novel Tumor Suppressor Gene in Medulloblastoma	Sidharth Mahapatra
FRIDAY	PDTM-15	Identification and Characterization of Wilms' Tumor Protein in Pediatric Midline Gliomas	Sulgi Lee
SATURDAY	PDTM-16	An Improved Diffuse Intrinsic Pontine Glioma Model Initiated in olig2-expressing Progenitors of the Neonatal Brainstem	Yosuke Shimazu
FRIDAY	PDTM-17	Dual Targeting of SHH Signaling and Bcl-xl Function as a Novel Treatment for Medulloblastoma	Katherine Veleta
FRIDAY	PDTM-19	Tumour Treating Fields (TTFields) Exhibit Efficacy on High-grade Paediatric Brain Tumour Cell Lines	Joshua Branter
SATURDAY	PDTM-20	Elucidating Molecular Pathogenic Mechanisms of the Histone H3.3 G34R Mutation in Pediatric High-grade Gliomas (HGGs)	Santiago Haase
SATURDAY	PDTM-22	Targeting a Novel Metabolic Defect in ppm1d-mutant Diffuse Intrinsic Pontine Gliomas	Nathan Fons
FRIDAY	PDTM-23	CD57 Defines a Novel Marker of Glioblastoma Stem Cells That Drives the Invasion of GBM	Lin Qi
SATURDAY	PDTM-32	The Novel Therapeutic Curcumin Enhances Targeted Bacteriophage Mediated <i>in-vitro</i> cell Death in Primary Human Diffuse Intrinsic Pontine Glioma	Gargi Samarth
FRIDAY	PDTM-35	Genetic Alterations Driving Spinal Intramedullary Metastases of a Histone-mutated Diffuse Midline Pineal Glioma	Christopher Hong
SATURDAY	PDTM-36	New Therapeutic Approach for Brainstem Glioma: Intranasal Delivery of Nanoliposomal SN-38	Xingyao He

FRIDAY	PDTM-39	Histone H3 Mutation Effects on Chromatin Structure and Regulation of Gene Transcription in Pediatric Glioma	Amanda Saratsis
SATURDAY	PDTM-42	Targeted Inhibition of BET Bromodomain and JMJD3 Proteins for the Treatment of Diffuse Intrinsic Pontine Glioma	Hiroaki Katagi
FRIDAY	PDTM-43	The Role of Tumor Associated Macrophages in Pediatric High-grade Glioma	James Ross
SATURDAY	PDTM-44	Intracranial Ependymoma: Developing Preclinical Models and Identifying Novel Treatments	Ashleigh Lester
FRIDAY	PDTM-45	Positive Modulation of Native Gabaa Receptors in Medulloblastoma Cancer Cells with Benzodiazepines Induces Rapid Mitochondrial Fragmentation and tp53-dependent, Cell Cycle-independent Apoptosis	Daniel Pomeranz Krummel
FRIDAY	QOLP-01	Effects of Tumor Treating Fields on Health-related Quality of Life (HRQoL) in Newly Diagnosed Glioblastoma: An Exploratory Analysis of the EF-14 Randomized Phase III Trial	Tobias Walbert
SATURDAY	QOLP-04	The Evolving Role of Complementary Cannabis Therapy in Glioblastoma Treatment	Nicholas Blondin
FRIDAY	QOLP-05	The Effect of Resilience on Quality of Life in Patients with High Grade Gliomas and Their Caregivers	Laura Donovan
SATURDAY	QOLP-06	Body Image Disturbance in Patients with Primary Brain Tumors	Lindsay Rowe
FRIDAY	QOLP-07	Quality of Life in Patients with Meningioma	Maryam Shahin
SATURDAY	QOLP-10	The Impact of Various Factors on Health-related Quality of Life (hrQOL) in Patients Undergoing Intracranial Radiotherapy	Jeffrey Burkeen
FRIDAY	QOLP-11	Quality of Life in High-grade Glioma Patients on a Phase I Virotherapy Study	Christina Amidei
FRIDAY	QOLP-13	Psychosocial Distress in Patients with Recurrent Meningiomas	Dina Randazzo
SATURDAY	QOLP-14	Preliminary Examination of Confirmed Glioma Risk Factors Among Ependymoma Patients in the Neuro-oncology Branch Natural History Study (NOB-NHS) and Risk and Outcomes Study (ROS)	Alvina Acquaye
FRIDAY	QOLP-15	Safety and Adverse Event Profile of Tumor Treating Fields in Anaplastic Glioma – a Post-marketing Surveillance Analysis	Daniela A. Bota
SATURDAY	QOLP-16	Capturing the Primary Brain Tumor (PBT) Patient's Experience of Body Image Dissatisfaction: Report from the Neuro-oncology Branch-natural History Study (NOB-NHS)	Alvina Acquaye
FRIDAY	QOLP-17	Review and Meta-analysis of Nausea and Vomiting Trials for Malignant Gliomas	Mary Affronti
SATURDAY	QOLP-18	Psychological Intervention Applied to Minimizing the Use of Sedatives in 3-14 Years Old Central Nerve System Tumors Undergoingradiotherapy	Lin Bo Cai
SATURDAY	QOLP-22	The International Low Grade Glioma Registry: Patient-reported Quality of Life	Elizabeth Claus
FRIDAY	QOLP-23	Palliative Care and End of Life Healthcare Utilization in Patients with Incurable Primary Malignant Brain Tumors	Sunil Bhatt
SATURDAY	QOLP-24	Attitudes Toward Fertility and Fertility Preservation in Women with Glioma	Rachel Stiner
FRIDAY	QOLP-27	Use of Complementary and Alternative Medicine in Glioma Patients	Caroline Hertler
SATURDAY	QOLP-28	Fear of Dying in Adult Primary Brain Tumor Patients: Age and Gender Effects	Ashlee Loughan
FRIDAY	RARE-01	In vivo Immunomodulating Effect of LXR-623 and Its Synergism with Checkpoint Blockade Against Chordomas in a Humanized Mouse Model	Wataru Ishida

SATURDAY	RARE-02	Primary CNS Posttransplant Lymphoproliferative Disease (PCNS-PTLD): <i>recognizing the Entity, Minimizing Treatment Toxicity, and Development of Surveillance Tools in Renal Transplant Patients</i>	Na Tosha Gatson
FRIDAY	RARE-03	Characteristics of Patients with Neurocutaneous Melanosis: The MSK Experience from 2003-2018	Yasmin Khakoo
SATURDAY	RARE-04	PDL1 Loss of Expression in a Metastatic Carcinoma of Unknown Primary with Hepatoid Features Treated with Nivolumab	Katherine Wagner
FRIDAY	RARE-05	Tumor Profiling Reveals Epithelial-to-mesenchymal Transition (EMT) and Enhanced Immune Suppression in Gliosarcomas Relative to Glioblastoma	Christopher Dardis
FRIDAY	RARE-07	The Effect of Selumetinib on Spinal Neurofibromas in Patients with NF1	Sadhana Jackson
SATURDAY	RARE-08	Grading Considerations for Meningeal Solitary Fibrous Tumor/hemangiopericytoma	Caterina Giannini
SATURDAY	RARE-10	Initial Experience in Ependymoma with Investigational Cancer-targeting BXQ-350 Sapc-dops Nanovesicles: A Rare Tumor Case Study	Vinay Pudevalli
FRIDAY	RARE-11	Efficacy and Safety of Dabrafenib + Trametinib in Patients with Recurrent/refractory <i>braf</i> v600e-mutated Low-grade Glioma (LGG)	Patrick Wen
FRIDAY	RARE-13	Characterization of Adult Medulloblastoma Patients at Recurrence: Retrospective Review of the MD Anderson Cancer Center Experience	Nazanin Majd
SATURDAY	RARE-16	Clinical and Histopathological Characteristics of Young Adults with Glioblastoma at Diagnosis	Zachary Vaslow
FRIDAY	RARE-17	Lenalidomide as Treatment for Relapsed or Refractory Primary CNS Lymphoma: A Single Institutional Experience	Donna Molaie
SATURDAY	RARE-18	Osteosarcoma and Medulloblastoma in a Li-fraumeni Patient	Ronald Hamilton
FRIDAY	RARE-19	Chemotherapy for Spinal Gliomas in Adults: A Retrospective Study	Dorothee Gramatzki
SATURDAY	RARE-20	BRAF Mutations in Pediatric Gangliogliomas and the Clinical Significance – an MD Anderson Cancer Center Experience	Sheetal Phadnis
FRIDAY	RARE-21	A Descriptive Report of Patients with Rare Central Nervous System (CNS) Cancers on an Nci-connect Cancer Moonshot Immune Checkpoint Inhibitor Trial	Lisa Boris
SATURDAY	RARE-22	Frequent High Tumor Mutational Burden (TMB) and PD-L1 Expression in Primary CNS Lymphoma (PCNSL)	Ashley Sumrall
FRIDAY	RARE-23	Primary Intra-axial Central Nervous System Inflammatory Myofibroblastic Tumor, ALK Negative: A Rare Entity	Nicholas Pflederer
SATURDAY	RARE-26	Mutations in MAPK Pathway Genes Are Characteristic and Confirmatory of Multinodular and Vacuolating Neuronal Tumor of the Cerebrum	Orwa Aboud
FRIDAY	RARE-27	Chimeric Spinal Cord Glioproliferative Lesion Following Intrathecal Fetal Stem Cell Infusion	Douglas Ney
SATURDAY	RARE-30	Case Series of Intracranial Non-germinomatous Germ Cell Tumor: A Single Institution Experience	Nidhi Shah
FRIDAY	RARE-31	Natural History of T-cell CNS Lymphoma	Akhilesh Padhye
SATURDAY	RARE-32	Extra-articular Tenosynovial Giant Cell Tumor of Diffuse Type in the Temporal Area with Brain Parenchymal Invasion	Young Seok Park
FRIDAY	RARE-35	Long-term Results of High-dose Methotrexate Treatment for Primary Central Nervous System Lymphoma. a Multi-institutional Experience	Dong-Sup Chung

SATURDAY	RARE-36	Malignant Pheochromocytoma Metastatic to Thoracic Vertebra: Palliative Neurosurgical Management	Esteban Ramirez Ferrer
FRIDAY	RARE-37	Occurrence of Glioma in Pregnant Patients: Institutional Case Series and Review of the Literature	Pawan Singh
SATURDAY	RARE-40	Personalized Medicine Diagnosis and Response to Treatment with Braf Mek Inhibitor in a Pleomorphic Xanthoastrocytoma Patient	Yolanda Pina
FRIDAY	RBTT-01	Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma	Manmeet Ahluwalia
SATURDAY	RBTT-02	Enhancing Vaccine Responses with Dose-intensified Temozolomide in Glioblastoma: Initiation of the I-ATTAC Trial	Kristen Batich
FRIDAY	RBTT-03	A Phase 1, Multicenter, Randomized, Open-label, Perioperative Study of AG-120 (ivosidenib) and AG-881 in Patients with Recurrent, Nonenhancing, idh1-mutant, Low-grade Glioma	Ingo Mellinghoff
SATURDAY	RBTT-04	Does Exercise Improve Progression Free Survival and Quality of Life in Patients with Glioblastoma? A Trial in Progress	Kim Edelstein
FRIDAY	RBTT-05	Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study	Minesh P Mehta
FRIDAY	RBTT-07	NUTMEG: A Randomised Phase II Study of Nivolumab and Temozolomide (TMZ) vs TMZ Alone in Elderly Patients with Newly Diagnosed Glioblastoma (GBM): Trial in Progress	Mustafa Khasraw
SATURDAY	RBTT-08	EORTC 1709/CCTG CE.8: A Phase III Trial of Marizomib in Combination with Standard Temozolomide-based Radiochemotherapy versus Standard Temozolomide-based Radiochemotherapy Alone in Patients with Newly Diagnosed Glioblastoma	Patrick Roth
FRIDAY	RBTT-09	The Efficacy of Ketogenic Diet with Concomitant Intranasal Perillyl alcohol as a Novel strategy for Therapy of Recurrent Glioblastoma	Clovis Fonseca
SATURDAY	RDNA-02	Tumor Treating Fields Differentially Alter Homologous Recombination in Patient Derived Glioma Cells versus Established Lines	Lawrence Bronk
FRIDAY	RDNA-03	Targeting the Epigenetic Remodeling Factor FACT to Radiosensitize Glioblastoma Cancer Stem Cells	Kristin Huntoon
SATURDAY	RDNA-04	Potential Mechanism of Temozolomide-mediated Radio-sensitization in MGMT Hypermethylated Glioblastoma Cells	Gaspar Kitange
SATURDAY	RDNA-06	A Novel Role of SGEF in Mediating GBM Cell Survival by Modulating the DNA Damage Repair Mechanism	Serdar Tuncali
FRIDAY	RDNA-07	idh1-mutant Glioblastoma (GBM) Cells from a Patient Post-tumor Treating Fields (TTFields) Therapy Are Sensitive to TTFields <i>in vitro</i>	Sandeep Mittal
FRIDAY	RDNA-09	Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells	Joseph McAbee
SATURDAY	RDNA-10	Histopathological and Genomic Characterization of Glioblastoma (GBM) Resected After Tumor Treating Fields (TTFields) Therapy	Sharon Michelhaugh
FRIDAY	RDNA-11	Overcoming Radiation Resistance in meningioma: the Emerging Role of CDK4/6 Inhibitor	Arabinda Das
SATURDAY	RDNA-12	ATR Inhibitor VE-822 Is a Novel Radio-sensitizer for Glioma	Vineshkumar Thidil Puliappadamba
FRIDAY	RDNA-13	Validation of Behavioral Analysis Across Age in a Mouse Model for Future Investigation of Radiation-induced Hypersomnolence (RIH) in Primary Brain Tumor (PBT) Patients	Caitlin Figiel

SATURDAY	RDNA-14	Identification of Novel Radiosensitizers in Glioblastoma Cancer Stem-like Cells	Elisabeth Anne Adanma Obara
SATURDAY	RDNA-16	The Role of RAD52 in Genomic Instability and Therapeutic Resistance of Malignant Gliomas	Kirstine Juul Elbæk
FRIDAY	RDNA-17	Power Density Loss Can Be Used to Defined Tumor Treating Fields Dose	Zeev Bomzon
FRIDAY	RTHP-01	Does the Efficacy of Salvage Re-irradiation in Recurrent Medulloblastoma Depend upon Risk-stratification, Site of Relapse, and Molecular Subgroup?	Tejpal Gupta
FRIDAY	RTHP-03	Timing of Radiation Therapy After Surgical Resection of Intracranial Non-small Cell Lung Cancer Metastases: A Retrospective Analysis in 28 Patients	Sophie Peeters
FRIDAY	RTHP-09	Dysregulation of Wnt Signaling Pathway Correlates with Treatment Outcome in Glioblastoma Multiforme	Baldassarre Stea
FRIDAY	RTHP-11	Reirradiation of Recurrent High Grade Gliomas: Outcomes and Prognostic Factors	Christopher Chapman
SATURDAY	RTHP-12	Comparative Analysis of Tumor Treating Fields Using Conventional versus Alternative Array Placement for Posterior Fossa Glioblastoma	Eric Wong
FRIDAY	RTHP-13	Tumor-treating Fields Therapy Is Compatible with Standard Chemoradiotherapy for Glioblastoma	Lawrence Kleinberg
SATURDAY	RTHP-14	Tumor-treating Fields for Glioblastoma: Numerical Simulation Explores Sub-cellular Mechanisms	Kristen Carlson
SATURDAY	RTHP-16	Radiation Induced Signal Changes on Magnetic Resonance Imaging in Adult Patients with Brain Tumors Treated with Pencil Beam Scanning Proton Therapy	Warissara Rongthong
FRIDAY	RTHP-17	Patterns of Re-irradiation for Recurrent Gliomas and Validation of a Prognostic Score	Joost Verhoeff
SATURDAY	RTHP-18	Post-operative Radiotherapy for Patients with Functioning and Non-functioning Pituitary Adenomas: A Systematic Review and Meta-analysis of 7551 Cases	Nardin Samuel
SATURDAY	RTHP-20	Pediatric High Grade Gliomas: Patterns of Failure and Outcomes with Limited Margin Radiotherapy	Tiffany Morgan
SATURDAY	RTHP-22	Radiation-induced Central Demyelination, a Rare Subacute Complication in 2 Cases	Christopher Trevino
FRIDAY	RTHP-23	Hearing and Facial Preservation for Vestibular Schwannomas Treated with Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy	Komal Preet
SATURDAY	RTHP-24	Clinical Features of Basal Ganglia Germ Cell Tumors and Its Clinical Outcomes	Lin Bo Cai
FRIDAY	RTHP-25	Therapeutic Effect of SRS in 34 Cases of Brain Metastases of NSCLC with a Maximum Diameter $\geq$ 4cm and Analysis of Prognostic Factors	Lin Bo Cai
SATURDAY	RTHP-26	Analysis of Outcomes from Re-irradiation with Pulsed Reduced Dose Rate Radiation Therapy for High Grade Gliomas	Adam Burr
FRIDAY	RTHP-27	Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-grade Glioma: A Single Institution Experience of 10 Years	Chibawanye Ene
SATURDAY	RTHP-28	Repeat Salvage Gamma Knife Radiosurgery for Recurrent Glioblastoma	Mujtaba Soniwala
FRIDAY	RTHP-29	A Feasibility Study of Radiation Therapy Dose Escalation Guided by Spectroscopic MRI in Patients with Glioblastoma	Eric Mellon
SATURDAY	RTHP-30	Management of Glioblastoma in the Elderly - A 10-year Analysis of the BC Cancer Agency Population	Jonathan Zeng
FRIDAY	RTHP-31	Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma	Susan Wu

FRIDAY	RTHP-33	Application of Presurgical Navigated Transcranial Magnetic Stimulation Motor Mapping for Adjuvant Radiotherapy Treatment Planning in Patients with Brain Tumors	Christian Diehl
SATURDAY	RTHP-34	Craniospinal Irradiation (CSI) as Part of Re-irradiation (RT2) for Children with Recurrent Intracranial Ependymoma	Derek Tsang
FRIDAY	RTHP-35	Survival Impact of Delays Prolonging the Overall Duration of Adjuvant Radiation Therapy for Patients with Glioblastoma	Mehran Yusuf
FRIDAY	RTHP-37	Impact of 11c-methionine/fdg Dural Tracer Pet-based, Compared with Mri-based Target Delineation of Malignant Gliomas for Radiation Planning	Manabu Kinoshita
SATURDAY	RTHP-38	BNCT Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas	Shin-Ichi Miyatake
FRIDAY	RTHP-39	Single Arm, Multi-centric Phase II Clinical Study Named "Boron Neutron Capture Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma Multiforme"	Shin-Ichi Miyatake
SATURDAY	RTHP-40	Endocrine and Metabolic Abnormalities in Intracranial Germ Cell Tumor Patients Treated with Irradiation	Xiang Boni
FRIDAY	RTHP-41	Long-term Stroke Risk in Meningioma Patients Treated with Conventionally Fractionated Photon-based Radiation Therapy	Shearwood McClelland III
SATURDAY	STEM-02	Developing Brain Metastatic Tumor Models for Targeted Stem Cell Therapy	Yohei Kitamura
SATURDAY	STEM-04	Glioma Stem Cell Regulator S100A4 Modulates GBM Immune Landscape	Kyuson Yun
FRIDAY	STEM-05	Identification of Patient-derived Glioblastoma Stem Cell (GSC) Lines with the Alternative Lengthening of Telomeres Phenotype	Ahsan Farooqi
SATURDAY	STEM-08	Modulation of Radiation-induced Mesenchymal Stem Cell Migration in Glioblastoma	Daniel Trifiletti
FRIDAY	STEM-09	Cancer Stem Cell Immunoediting	Loic Deleyrolle
SATURDAY	STEM-10	Molecular Mechanisms Underlying Phenotypic Plasticity in Malignant Glioma	Costanza LoCascio
SATURDAY	STEM-14	Growth Factor Receptor Co-inheritance During Asymmetric Cell Division Drives the Cancer Stem Cell Phenotype	Masahiro Hitomi
FRIDAY	STEM-15	CDK5 and Notch Signaling Crosstalk Drives Self-renewal in Gscs	Subhas Mukherjee
SATURDAY	STEM-16	stox2, a New Regulator for GBM Stem Cell Maintenance and Immune Response	Dan Jin
FRIDAY	STEM-17	Spatial Identity of Glioblastoma Cells Defines Therapy-induced Clonal Competition	Anutosh Ganguly
SATURDAY	STEM-18	The C-jun N-terminal Kinase (JNK) Is a Crucial Component of Maintenance in Glioblastoma Stem-like Cells	Arlet Maria Acanda de la Rocha
FRIDAY	STEM-19	Monocarboxylate transporter-4 Depletion Inhibits Stemness, Promotes DNA Damage and Radiosensitizes Glioblastoma Stem Cells	Raffaella Spina
SATURDAY	STEM-20	<i>spt6</i> Regulates transcription by Stabilizing RNA Pol II and so Drives Glioblastoma Cancer Stem-like Cell Maintenance	Alex Frias
FRIDAY	STEM-21	Deciphering the Response of Subventricular Zone-nested Glioblastoma Cells After Surgery	Arnaud Lombard
SATURDAY	STEM-22	Uptake of <i>p</i> -borono-phenylalanine by Brain Tumor Stem Like Cells Analyzed by Mass Cytometry	Natsuko Kondo
SATURDAY	STEM-26	Microenvironmental FGF2 Induces Glioblastoma Stem Cells Through the FGFR1-ZEB1 Axis	Florian Siebzehnubel
FRIDAY	STEM-27	The Alteration of Immunosuppressive Function in Glioblastoma with Undifferentiated Transformation	Shun Yamamuro

FRIDAY	SURG-01	An Intraoperative Raman Spectroscopic Probe for Glioma Surgery: Indications, Safety, and Future Directions	Thomas Noh
FRIDAY	SURG-03	A Comparison of Survival Outcomes After Biopsy versus Resection in Primary CNS Lymphoma: A Single Institution Experience	Christopher Hong
SATURDAY	SURG-04	Survival Benefit Associated with Gross Total Resection in Grade II Astrocytomas: An Integrated Analysis of the SEER and TCGA Database	Ali Alattar
SATURDAY	SURG-08	Survival Benefit of Lobectomy for Primary Glioblastomas in Non-eloquent Region: Gross-total Resection versus Supratotal Resection	Minkyun Na
FRIDAY	SURG-09	Awake Craniotomy for Brain Tumor in Octogenarians and Nonagenarians	Tomasz Polis
SATURDAY	SURG-10	Microsurgery of Limbic and Paralimbic Gliomas: Extent of Resection, Morbidity and Survival	Cristina Goga
FRIDAY	SURG-11	Pathological Investigation of Novel Spray-type Fluorescent Probes for Brain Tumors	Shota Tanaka
SATURDAY	SURG-12	Anterior Skull Base Tumor Resection by Transciliary Supraorbital Keyhole Craniotomy	Ya-Jui Lin
FRIDAY	SURG-15	Upfront Mri-guided Stereotactic Laser-ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-only Patients	Alireza Mohammadi
SATURDAY	SURG-16	MRI Neuronavigation-guided Resection for Recurrence-initiating GBM Clones	Ichiro Nakano
FRIDAY	SURG-17	Combined Awake Craniotomy and Transcortical MEP for Resection of Motor Area Gliomas	Taiichi Saito
SATURDAY	SURG-18	Comparison of Survival Outcomes Between Partial Resection and Biopsy for Primary Glioblastoma: A Propensity Score-matched Study	Joonho Byun
FRIDAY	SURG-19	Impact of Intraoperative Magnetic Resonance Imaging on the Extent of Resection and Functional Outcome in Awake Surgery for Eloquent Gliomas – A Single Center Retrospective Study	Christine Jungk
SATURDAY	SURG-20	Laser-interstitial Thermal Therapy versus Craniotomy for Treatment of Radiation Necrosis or Recurrent Tumor in Brain Metastases Failing Radiosurgery	Christopher Hong
FRIDAY	SURG-21	Supracerebellar Transtentorial Approach for Occipital Meningioma to Maximize Visual Preservation: Technical Note	Danielle Golub
SATURDAY	SURG-22	Supratotal Resection in Glioma: A Systematic Review	Charles de Leeuw
FRIDAY	SURG-23	Clinical Results After Surgical Resection of Parasagittal Meningiomas in Patients Using a Nd-yag Laser in the Distal Postoperative Period	Aleksei Buzunov
FRIDAY	SURG-25	Intramedullary Spinal Cord Tumours – A Single United Kingdom Centre Ten-year Analysis	Oliver Richards
FRIDAY	TMIC-01	LOX Dependent Macrophage Recruitment in GBM	Y. Alan Wang
SATURDAY	TMIC-02	Interaction of Ligand Conjugated Quantum Dots with the Glioma Stem Cell Secreted Exosomes and Subsequent Uptake by the Glioma Stem Cells of Various Subtypes	A.B. Madhankumar
FRIDAY	TMIC-03	Dissecting glioma:immune Cell Interactions at the Single Cell Level	Kyuson Yun
SATURDAY	TMIC-06	Deficiency of mirna-146a-5p Contributes to Transformation of Glioma-derived Mesenchymal Stromal/stem Cells via Targeting HNRNPD	Jun Dong
FRIDAY	TMIC-07	Hypoxic Microenvironment Confers Specific Alterations in DNA Methylation Profiles in Glioblastoma	Sheila Mansouri

SATURDAY	TMIC-08	CHD7 Is Suppressed in the Perinecrotic/ischemic Microenvironment and Is a Novel Regulator of Angiogenesis	Nathaniel Boyd
FRIDAY	TMIC-09	Excitatory Synapses Between Presynaptic Neurons and Postsynaptic Glioma Cells Promote Glioma Progression	Humsa Venkatesh
SATURDAY	TMIC-10	Autopsy Study on the Effects of Tumor Treatment Fields in Recurrent Glioblastoma: Preliminary Results	Alexander Barrington
SATURDAY	TMIC-12	Tumor-homing Rna-nanoparticles Reprogram Immune Cells in the Brain Tumor Microenvironment	Adam Grippin
FRIDAY	TMIC-13	Efficacy of Retinoic Acid in Reversing Immune Evasion in IDH Mutant Gliomas	Aparna Rao
FRIDAY	TMIC-17	Immune Microenvironment of nf2-altered Radiation-induced Meningiomas	Suganth Suppiah
SATURDAY	TMIC-18	Impact of HFE Mutation on Viability in Macrophages Exposed to Glioblastoma Exosomes	Darya Nesterova
FRIDAY	TMIC-19	Using Quantitative MR Imaging to Relate GBM Mass Effect to Perfusion and Diffusion Characteristics of the Tumor Micro-environment	Daniel Abler
SATURDAY	TMIC-20	Interstitial Fluid Flow Magnitudes Drive Changes to the Glioma Microenvironment	Jennifer Munson
FRIDAY	TMIC-21	The Potential Contribution of Pericytes to Glioblastoma Multiforme Tumour Micro-environment Immunosuppression via Dampened Expression of ICAM-1, VCAM-1 and MCP-1	Jena Macapagal
SATURDAY	TMIC-22	Exosomal Non-coding Rnas Mediate the Cross-talk of Brain Metastasis Cancer Stem Cells and Microglia	Chaya Brodie
FRIDAY	TMIC-23	Chemotherapy and Tau Interplay Facilitates Breast to Brain Metastasis	Josh Neman
SATURDAY	TMIC-26	mir-181a Controls the Osteopontin-mediated Immune Circuit in Glioblastoma	Anantha Marisetty
FRIDAY	TMIC-27	Glioma Cells Induce 'Epigenetic Memory' in Microglia and Block Inflammatory Gene Expression- in vitro and in vivo Findings	Bozena Kaminska
SATURDAY	TMIC-32	Inhibition of Merck Modulates Glioma-associated Macrophages and Microglia in Tumor Microenvironment	Yu-Ting Su
FRIDAY	TMIC-33	The Role of Fibrinogen-like Protein 2 on Immunosuppression and Malignant Progression in Glioma	Ganesh Rao
FRIDAY	TMIC-35	Astrocyte-dependent Enhancement of Glioblastoma Growth as a Candidate Therapeutic Target	Alessandro Mega
SATURDAY	TMIC-36	Local Tissue Biomarkers of Response to Therapy for Glioblastoma	Karishma Rajani
FRIDAY	TMIC-37	Targeting the Extracellular Matrix of Glioblastomas Changes the Polarization of Tumor-associated Macrophages and Increases Anti-tumor Inflammatory Responses	Mariano Viapiano
SATURDAY	TMIC-38	Enhanced Efficacy of Tumor Treating Fields and Aurora B Kinase Inhibitor Combination in Glioma Cell Lines	Moshe Giladi
FRIDAY	TMIC-39	Unravelling the Tumour Microenvironment of Glioma	Viive Howell
FRIDAY	TMIC-41	Apoptotic Cells Promote Malignancy of Surviving Glioblastoma Cells by Intercellular Transfer of Splicing Factors	Soniya Bastola
SATURDAY	TMIC-42	Development of Novel Spray-type Fluorescent Probes for Brain Tumors	Yosuke Kitagawa
FRIDAY	TMIC-43	A Tension-mediated Glycocalyx Feedback Loop Promotes a Mesenchymal, Stem-like Phenotype in Glioblastoma	Shelly Kaushik

SATURDAY	TMIC-44	Astrocyte Senescence: A Model for Age and Sex Effects on Glioblastoma Incidence	Cameron Hill
FRIDAY	TMIC-45	Oligodendrocyte Progenitor Cells and Macrophages/microglia Induce Chemo-radioresistant Abilities in Glioma Cells at the Tumor Border	Takuichiro Hide
FRIDAY	TMIC-47	Glioma Stem Cell-vascular Interface in Glioblastoma Progression	Sree Deepthi Muthukrishnan
SATURDAY	TMIC-48	Dynamic of Microglia Polarization in Glioma Tumor Resection Area	Jescelica Ortiz
SATURDAY	TMIC-50	Hyperactivating the Hippo Pathway Effector TAZ Distorts the Tumor Microenvironment, Promotes Tumor-entrained Neutrophil Infiltration, and Phenocopies Mesenchymal-glioblastoma	Patricia Yee
FRIDAY	TMIC-51	Dexamethasone Drives Myeloid-derived Suppressor Cell Accumulation in Glioblastoma in a Sex-specific Manner	Defne Bayik
SATURDAY	TMIC-52	Dexamethasone-mediated Activation of Fibronectin Matrix Assembly Inhibits Dispersal of Human Primary GBM Cells in a Mouse Retina in vivo Model	Arthur Carminucci
FRIDAY	TMIC-53	Identification of Myeloid Cell-derived Transcripts in Glioblastoma	Frank Szulzewsky
SATURDAY	TMIC-54	The Impact of Glioma Cancer Cell Stemness on Exosome Phenotype	Oliver Mrowczynski
FRIDAY	TMOD-01	The Role of Persistence, Proliferation, and Tumor Cell Killing Efficiency in Determining Response to CAR T-cell Therapy in Glioblastoma: A Mathematical Model and Analysis	Prativa Sahoo
SATURDAY	TMOD-02	Diffuse Gliomatosis in Mouse Model of GFAP Tissue Specific Knock in of Egfrviii and Knock out of p19 ARF	Mira Li
SATURDAY	TMOD-04	Targeting a Glioma Specific Lncrna in a Human Brain Organoid Tumor Model	Martina Malatesta
FRIDAY	TMOD-05	glioma-261 Luciferase-expressing Cell Line Stimulates an Immunogenic Response Signature in an Immunocompetent Murine Model	Victoria Sanchez
SATURDAY	TMOD-06	High Incidence of Tumors After Treatment with a Dna-alkylating Agent in Mouse Strains Commonly Used in Pre-clinical Studies	Ana deCarvalho
FRIDAY	TMOD-07	Localization of Erlotinib Relative to Mri-based Tumor Extent in PDX Glioblastoma Model: Towards a Mathematical Model for the Interface Between MRI and Drug Distribution	Pamela Jackson
SATURDAY	TMOD-08	Growth Impairment Under Conditions Favoring Mitochondrial Oxidative Metabolism in a Yeast Model of Cancer-associated Isocitrate Dehydrogenase Mutation	Sophie Fiola
SATURDAY	TMOD-10	Metabolic and Blood-brain Barrier Markers for Fluorescence-guided Surgery: Systematic High-resolution Microscopy Investigation in Human Relevant Experimental Gliomas	Evgenii Belykh
FRIDAY	TMOD-11	Imaging Based Invasion Metric Predictive of Response to ABT414 in Orthotopic Egfrviii Amplified Patient Derived Xenografts	Susan Christine Massey
FRIDAY	TMOD-13	A Novel 3D High-resolution Histopathological Image Reconstruction Method versus Common 2D and 3D Imaging Methodologies for Application in Cancer Spheroid Research: Which Is Better?	James Samarasekara
SATURDAY	TMOD-14	A Patient-derived Cancer Cell Line Atlas of Primary and Metastatic Central Nervous System Tumors	Frederik De Smet
FRIDAY	TMOD-15	Reliability of Imaging-based Measures of Tumor 'Mass-effect'– Evidence from a Computational Study	Daniel Abler
SATURDAY	TMOD-16	Comparing the Effects of Circumscribed versus Infiltrative Tumor Growth Patterns on Functional Connectivity, Hemodynamic Parameters, and Behavior in a Mouse Glioma Model	Inema Orukari

FRIDAY	TMOD-17	A Novel Adenoviral-permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma	Lynette Phillips
SATURDAY	TMOD-18	The Patient Derived Xenograft National Resource: A Comprehensive Collection of High-grade Glioma Models for Pre-clinical and Translational Studies	Rachael Vaubel
SATURDAY	TMOD-20	<i>tr</i> king down Novel Therapeutic Targets in Gliomas	Barbara Oldrini
FRIDAY	TMOD-21	Neuro-oncological Animal Models and Peritumoural Oedema - In the Blind Spot?	Moritz Schramm
SATURDAY	TMOD-22	Modeling Sex Differences in p53 Gain-of-function Mutations in Glioblastoma	Nathan Rockwell
FRIDAY	TMOD-25	Modeling idh1-mutated Gliomas: Generation, Characterization and Therapeutic Sensitivities of Seven Patient-derived idh1-mutant Glioma Cell Lines	Cassandra Verheul
SATURDAY	TMOD-26	Cytomegalovirus Promotes Glioblastoma Growth via PDGF-D Driven Pericyte Recruitment and Angiogenesis	Sean Lawler
SATURDAY	TMOD-28	MYC Overexpression Drives Medulloblastoma from Human Neuroepithelial Stem Cells	Sonja Hutter
FRIDAY	TMOD-29	Molecular Characterization of Glioma Patient-derived Orthotopic Xenografts: From Basic Research to Preclinical Studies	Ann-Christin Hau
SATURDAY	TMOD-30	anti-pd-l1 Antibody Enhances Radiation Induced Abscopal Response in Murine Brain Tumors	Chibawanye Ene
SATURDAY	TMOD-32	Generation of Glioblastoma Patient Derived Intracranial Xenografts for Preclinical Studies	Amber Kerstetter-Fogle
SATURDAY	TMOD-34	Improved Treatment of Melanoma Brain Metastasis Using a Synthetic Peptide	Synnove Aasen
FRIDAY	TMOD-37	In vivo Synergistic Effect of Checkpoint Blockade and Radiation Therapy Against Chordomas in a Humanized Mouse Model	Sheng-fu Lo
SATURDAY	TMOD-38	GMYC: A Novel Inducible Transgenic Model of Group 3 Medulloblastoma	Gabriela Rosén
FRIDAY	TMOD-39	A Platelet-activating Factor Receptor Antagonist Delays Glioblastoma Growth and Invasion in a Mouse Model	Valerie Cruz Flores